Document:

Exhibit 10.2

            

            

            

            
            QUALITY SYSTEMS, INC.

            
            AMENDED AND RESTATED

             

            
            2005 STOCK OPTION

            
            AND

            
            INCENTIVE PLAN

             

            
            ARTICLE I

            
            GENERAL

            
            1.1   
            Purpose. The purpose of the Quality
            Systems, Inc. Amended and Restated 2005 Stock Option and Incentive Plan (the
            “Plan”) is to promote
            the future success of Quality Systems, Inc. (the
            “Company”) by providing
            an incentive for officers, employees and directors of, and consultants and advisors to,
            the Company and its Related Entities to acquire a proprietary interest in the success
            of the Company, to remain in the service of the Company and/or Related Entities, and to
            render superior performance during such service.

            
                	
                             

                        	
                            
                            1.2

                        	
                            
                            Definitions of Certain
                            Terms.

                        

            

            
            (a)          
            “Award”
            means an award under the Plan as described in
            Section 1.5 and
            Article II.

            
            (b)          
            “Award
            Agreement” means a written agreement entered into
            between the Company and a Grantee in connection with an Award.

            
                	
                             

                        	
                            
                            (c)

                        	
                            
                            “Board
                            ” means the Board of Directors of the
                            Company.

                        

            

            
            (d)          
            “Cause.”
            Termination of Employment by the Company for
            “Cause” means, with
            respect to a Grantee and an Award, (i) except as provided otherwise in the applicable
            Award Agreement or as provided in clause (ii) below, Termination of Employment of the
            Grantee by the Company (A) upon Grantee’s failure to substantially perform
            Grantee’s duties with the Company or a Related Entity (other than any such
            failure resulting from death or Disability), (B) upon Grantee’s failure to
            substantially follow and comply with the specific and lawful directives of the Board or
            any officer of the Company or a Related Entity to whom Grantee directly or indirectly
            reports, (C) upon the Board’s determination of Grantee’s commission of an
            act of fraud or dishonesty resulting in actual economic, financial or reputational
            injury to the Company or a Related Entity, (D) upon the Board’s determination of
            Grantee’s engagement in illegal conduct, gross misconduct or an act of moral
            turpitude, involving economic, financial or reputational injury to the Company or a
            Related Entity, or (E) upon Grantee’s material violation of any material written
            policy, guideline, code, handbook or similar document governing the conduct of
            directors, officers or employees of the Company or its Related Entities resulting in
            actual economic, financial or reputational injury to the Company or

             

            
            1

             

            
            

            

            

            
            Related Entity; or (ii) in the case of directors, officers or employees
            who at the time of the Termination of Employment (A) are entitled to the benefits of a
            change in control, employment or similar agreement entered into by the Company or a
            Related Entity or (B) are subject to an existing Company policy or agreement, that
            defines or addresses termination for cause, termination for cause as defined and/or
            determined pursuant to such agreement.

            
                	
                             

                        	
                            
                            (e)

                        	
                            
                            “Code
                            ” means the Internal Revenue Code of 1986, as
                            amended.

                        

            

            
            (f)           
            “Committee”
            means a compensation committee appointed by the Board in accordance with
            Section 1.3(a) of the Plan.
             

            
                	
                             

                        	
                            
                            (g)

                        	
                            
                            “Common
                            Stock” means the common stock of the
                            Company.

                        

            

            
            (h)          
            “Disability”
            means, with respect to a Grantee and an Award, (i) except as provided in the applicable
            Award Agreement or as provided in clause (ii) below, “disability” as
            defined in (i) the long-term disability plan in which Grantee is participating; or (ii)
            in the case of directors, officers or employees who at the time of the Termination of
            Employment are entitled to the benefits of a change in control, employment or similar
            agreement entered into by the Company or a Related Entity that defines or addresses
            termination because of disability, “disability” as defined in such
            agreement; or (iii) if neither (i) nor (ii) apply, then such a plan in which any of the
            officers of the Company may be participating; or (iv) if (i), (ii) and (iii) do not
            apply, then as defined in Section 22(e)(3) of the Code. Notwithstanding the foregoing,
            (A) in the case of an Incentive Stock Option, the term
            “Disability” for
            purposes of the preceding sentence shall have the meaning given to it by
            Section 422 (c)(6) of the Code and (B) to the extent an Award is subject to the
            provisions of Section 409A of the Code and if in order for compensation provided
            under any Award to avoid the imposition of taxes under Section 409A of the Code, a
            different definition of “disabled” is required by Section 409A, the term
            “Disability” or
            “Disabled” for purposes
            of the preceding sentence shall have the meaning given to it by Section 409A
            (a)(2)(C) of the Code and the Regulations promulgated thereunder.

            
                	
                             

                        	
                            
                            (i)

                        	
                            
                            “Exchange
                            Act” means the Securities Exchange Act
                            of 1934, as amended.

                        

            

            
            (j)           
            “Fair Market
            Value” of a share of Common Stock on any date shall be
            (i) the closing sale price per share of Common Stock during normal trading hours
            on the national securities exchange, association or other market on which the Common
            Stock is principally traded for such date or the last preceding date on which there was
            a sale of such Common Stock on such exchange, association or market, or (ii) if
            the shares of Common Stock are then traded in an over-the-counter market or other
            market or association but the sale price for the Common Stock is not reported, the
            average of the closing bid and asked prices for the shares of Common Stock during
            normal trading hours in such over-the-counter market for such date or the last
            preceding date on which both the closing bid price and asked price are reported for the
            Common Stock, or (iii) if the shares of Common Stock are not then listed on a
            national securities exchange, association or other market or traded in an
            over-the-counter market, such value as the Board on advice

             

            
            2

             

            
            

            

            

            
            of the Committee and in the Board’s discretion shall determine,
            provided that such valuation shall take into account all available information material
            to the value of the company, including but not limited to the value of the tangible and
            intangible assets of the company, the present value of its anticipated future cash
            flows, the market value of the stock or equity interests in other entities engaged in
            substantially the same business, recent arm’s length transactions involving the
            sale of such stock, and other relevant factors.

            
                	
                             

                        	
                            
                            (k)

                        	
                            
                            “Grantee
                            ” means a person who receives an Award.

                        

            

            
            (l)           
            “Incentive Stock
            Option” means, subject to
            Section 2.3(f), a stock option that is
            intended to qualify for special federal income tax treatment pursuant to Sections 421
            and 422 of the Code (or a successor provision thereof) and which is so designated in
            the applicable Award Agreement. Under no circumstances shall any stock option that is
            not specifically designated as an Incentive Stock Option be considered an Incentive
            Stock Option.

            
            (m)         
            “Key
            Executive” means a Key Person who, on the last day of
            the Company’s taxable year, is either (i) the chief executive officer of the
            Company or acting in such capacity, or (ii) among the four highest compensated officers
            (other than the chief executive officer).

            
            (n)          
            “Key
            Persons” means then acting or prospective directors,
            officers and employees of the Company or of a Related Entity, and then acting or
            prospective consultants and advisors to the Company or a Related Entity.

            
                	
                             

                        	
                            
                            (o)

                        	
                            
                            “Non-Employee
                            Director” has the meaning given to it
                            in
                            Section 2.12(a).

                        

            

            
            (p)          
            “Performance
            Goals” means the objective goal(s) (or combined
            goal(s)) adopted by the Committee in its discretion to be applicable to a Key Executive
            with respect to an Award; such Performance Goals applicable to an Award may provide for
            a targeted or measured level or levels of achievement or change using any objective
            performance standard, including, but not limited to (and by way of example only): (i)
            revenue, (ii) earnings per share, (iii) net income, (iv) return on assets, (v) return
            on equity, (vi) stock price, (vii) economic profit or shareholder value added, (viii)
            total shareholder return, (ix) EBIT, and (x) EBITDA. Such measures may be defined and
            calculated in such objective manner and detail as the Committee in its discretion may
            determine, including whether such measures shall be calculated before or after income
            taxes or other items, the degree or manner in which various items shall be included or
            excluded from such measures, whether total assets or certain categories of assets shall
            be used, whether such measures shall be applied to the Company on a consolidated basis
            or to certain Related Entities of the Company or to certain divisions, operating units
            or business lines of the Company or a Related Entity, the weighting that shall be given
            to various measures if combined goals are used, and the periods and dates during or on
            which such measures shall be calculated. The Performance Goals may differ from Key
            Executive to Key Executive and from Award to Award. A Performance Goal is
            objective

             

            
            3

             

            
            

            

            

            

            
            if a third party having knowledge of the relevant facts could determine
            whether the Performance Goal is met.

            
            (q)          
            “Person,”
            whether or not capitalized, means any natural person, any corporation, partnership,
            limited liability company, trust or legal or contractual entity or joint undertaking
            and any governmental authority.

            
            (r)           
            “Related
            Entity” means any corporation, partnership, limited
            liability company or other entity that is an “affiliate” of the Company
            within the meaning of Rule 12b-2 under the Exchange Act.

            
            (s)          
            “Retirement”
            means, with respect to a Grantee and an Award, except as otherwise provided in the
            applicable Award Agreement, the Grantee’s Termination of Employment with the
            Company or a Related Entity for a reason other than for Cause and that at the time of
            the Termination of Employment the Grantee has satisfied the criteria for retirement in
            accordance with the Company’s employment policies if and when adopted by the
            Company.

            
                	
                            
                             

                        	
                            
                            (t)

                        	
                            
                            “Rule
                            16b-3” means Rule 16b-3 under the
                            Exchange Act.

                        

            

            
            (u)          
            A Grantee shall be deemed to have a
            “Termination of
            Employment” upon ceasing employment with the Company or
            any Related Entity (or, in the case of a Grantee who is not an employee, upon ceasing
            association with the Company or any Related Entity as a director, consultant, advisor
            or otherwise), provided, however, it
            shall not be considered a Termination of Employment of a Grantee if the Grantee ceases
            employment or association with the Company or a Related Entity but continues or
            immediately commences employment or association with a majority-owned Related Entity or
            the Company.

            
                	
                             

                        	
                            
                            1.3

                        	
                            
                            Administration.

                        

            

            
            (a)          
            The Committee. If such is required to
            assure compliance under Section 162(m), different Committees with respect to different
            groups of Key Persons may administer the Plan in accordance with this
            Section 1.3(a).

            
            (i)           
            Section 162(m). To the extent the Award is
            intended to qualify as “performance-based compensation” within the meaning
            of Section 162(m) of the Code, the Plan shall be administered by a Committee of two or
            more “outside directors” within the meaning of Section 162(m) of the
            Code.

            
            (ii)          
            Other Administration. Other than as
            provided above, the Plan shall be administered by (A) the Board through recommendations
            of the Compensation Committee as set forth herein, or (B) upon election and delegation
            by the Board, a Compensation Committee (including any successor thereto) of the Board
            which it may elect to act upon in its sole and absolute discretion, provided such
            Compensation Committee shall consist of not less than two independent
            directors.

             

            
            4

             

            
            

            

            

            

            
            (b)          
            Authority. The Committee shall advise the
            Board concerning the administration of the Plan and the Board’s actions which may
            be taken pursuant to the Plan. The Committee shall have the authority to recommend to
            the Board for Board approval: (i) the manner in which the Plan and any Award Agreement
            is construed, interpreted and implemented, (iii) amendments and rescission of
            rules and regulations relating to the Plan, including rules governing its own
            operations, (iv) determinations deemed necessary or advisable in administering the Plan
            (including defining and calculating Performance Goals and certifying that such
            Performance Goals have been met), (v) the correction of any defect, supplying any
            omission and reconciling any inconsistency in the Plan, (vi) amending the Plan to
            reflect changes in applicable law or regulations, (vii) whether, to what extent and
            under what circumstances Awards may be settled or exercised in cash, shares of Common
            Stock, other securities, other Awards or other property, or canceled, forfeited or
            suspended and the method or methods by which Awards may be settled, canceled, forfeited
            or suspended (including, but not limited to, canceling an Award in exchange for a cash
            payment (or securities with an equivalent value) equal to the difference between the
            Fair Market Value of a share of Common Stock on the date of grant and the Fair Market
            Value of a share of Common Stock on the date of cancellation, and, if no such
            difference exists, canceling an Award without a payment in cash or securities), and
            (viii) whether, and to what extent and under what circumstances cash, shares of Common
            Stock, other securities, other Awards or other property and other amounts payable with
            respect to an Award shall be deferred either automatically or at the election of the
            holder thereof or of the Board.

            
            (c)          
            Voting. Actions of the Committee shall be
            taken by the vote of a majority of its members. Any action may be taken by a written
            instrument signed by all of the Committee members, and action so taken shall be fully
            as effective as if it had been taken by a vote at a meeting.

            
            (d)          
            Binding Determinations. The determination
            of the Board on all matters relating to the Plan or any Award Agreement shall be final,
            binding and conclusive.

            
            (e)          
            Exculpation. No member of the Board or the
            Committee or any officer, employee or agent of the Company or any of its Related
            Entities (each such person a “Covered
            Person”) shall have any liability to any person
            (including, without limitation, any Grantee) for any action taken or omitted to be
            taken or any determination made in good faith with respect to the Plan or any Award.
            Each Covered Person shall be indemnified and held harmless by the Company against and
            from any loss, cost, liability or expense (including attorneys’ fees) that may be
            imposed upon or incurred by such Covered Person in connection with or resulting from
            any action, suit or proceeding to which such Covered Person may be a party or in which
            such Covered Person may be involved by reason of any action taken or omitted to be
            taken under the Plan and against and from any and all amounts paid by such Covered
            Person, with the Company’s approval, in settlement thereof, or paid by such
            Covered Person in satisfaction of any judgment in any such action, suit or proceeding
            against such Covered Person; provided
            that the Company shall have the right, at its own expense, to assume and
            defend any such action, suit or proceeding and, once the Company gives notice of its
            intent to assume the defense, the Company shall have sole control over such defense
            with counsel of the

             

            
            5

             

            
            

            

            

            
            Company’s choice subject to approval of the Covered Person (not to
            be unreasonably withheld). The foregoing right of indemnification shall not be
            available to a Covered Person to the extent that a court of competent jurisdiction in a
            final judgment or other final adjudication, in either case, not subject to further
            appeal, determines that the acts or omissions of such Covered Person giving rise to the
            indemnification claim resulted from such Covered Person’s bad faith, fraud or
            willful criminal act or omission. The foregoing right of indemnification shall not be
            exclusive of any other rights of indemnification to which Covered Persons may be
            entitled under the Company’s Articles of Incorporation or Bylaws, in each case as
            amended from time to time, as a matter of law, or otherwise, or any other power that
            the Company may have to indemnify such persons or hold them harmless pursuant to an
            indemnification agreement or otherwise (in which case, any conflict between the
            indemnification agreement or such other Board approved agreement shall be resolved in
            favor of the indemnification agreement or such other agreement).

            
            (f)           
            Experts. In making any determination or in
            taking or not taking any action under this Plan, the Committee or the Board, as the
            case may be, may obtain and rely upon the advice of experts, including professional and
            financial advisors and consultants to the Committee or the Company. No director,
            officer, employee or agent of the Company shall be liable for any such action or
            determination taken or made or omitted in good faith reliance on such
            advice.

            
            (g)          
            Board. Subject to the provisions of
            Sections 1.3(a)(i) and 1.7(b), but
            notwithstanding any other provision herein to the contrary (i) until the Board
            shall appoint the members of the Committee, the Plan shall be administered by the
            Board, and (ii) the Board may, in its sole discretion, at any time and from time
            to time, (A) grant Awards, (B) require that the Committee’s authority shall be
            limited to making recommendations to the Board concerning the granting and
            administration of the Plan and Awards hereunder, or (C) resolve to administer the Plan
            directly. In any of the foregoing events, the Board shall have all of the authority and
            responsibility granted to the Committee herein.
            Notwithstanding the foregoing, at any time during which the Board
            shall administer the granting of Awards, any Awards to the Chief Executive Officer and
            other executive officers of the Company shall be made by the Board meeting in executive
            session consisting entirely of independent directors (as defined in Rule 4350 of the
            Nasdaq Marketplace Rules).

            
            1.4          
            Persons Eligible for Awards. Awards under
            the Plan may be made to such Key Persons as the Committee shall select and recommended
            to the Board, provided that, to the extent an Award is subject to the provisions of
            Section 409A of the Code, such Key Person shall not be eligible to receive an
            Award of a stock right of a Related Person who is not either the entity to which the
            Key Person is providing direct services, or any corporation in a chain of a controlled
            group of corporations, beginning with the parent of the entity to which the Key Person
            is providing direct services and ending with the corporation that is receiving the
            services.

            
            1.5          
            Types of Awards Under the Plan. Awards may
            be made under the Plan including: (i) stock options, including Incentive Stock
            Options and non-qualified stock options, (ii) stock appreciation rights,
            (iii) restricted stock, (iv) unrestricted stock, (v) restricted stock
            units,

            
             

            
            6

             

            

            

            

           (vi) performance shares, (vii) performance units (including
            performance options), and other stock-based Awards, as set forth in
            Article II.

            
                	
                             

                        	
                            
                            1.6

                        	
                            
                            Shares Available for or Subject to
                            Awards.

                        

            

            
            (a)          
            Total Shares Available. The total number of
            shares of Common Stock that may be transferred pursuant to Awards granted under the
            Plan shall not exceed 1,200,000 shares. All of such shares shall be authorized for
            issuance pursuant to incentive stock options under
            Section 2.3 or for other Awards
            under Article II. Such shares
            may be authorized but unissued Common Stock. Any stock certificate evidencing shares
            issued pursuant to the Plan shall bear a legend setting forth such restrictions on
            transferability as may apply to such shares pursuant to the Plan. Such legend shall be
            caused to be removed by the Company’s Chief Financial Officer and Chief Executive
            Officer upon their joint written determination that the conditions warranting the
            inclusion of such legend are no longer applicable. If any Award is forfeited or
            otherwise terminates or is canceled without the delivery of shares of Common Stock,
            then the shares covered by such forfeited, terminated or canceled Award shall again
            become available for transfer pursuant to Awards granted or to be granted under this
            Plan. However, if any Award or shares of Common Stock issued or issuable under Awards
            are tendered or withheld as payment for the exercise price of an Award, the shares of
            Common Stock may not be reused or reissued or otherwise be treated as being available
            for Awards or issuance pursuant to the Plan. With respect to a stock appreciation
            right, both shares of Common Stock issued pursuant to the Award and shares of Common
            Stock representing the exercise price of the Award shall be treated as being
            unavailable for other Awards or other issuances pursuant to the Plan unless the stock
            appreciation right is forfeited, terminated or cancelled without the delivery of shares
            of Common Stock. Any shares of Common Stock delivered by the Company, any shares of
            Common Stock with respect to which Awards are made by the Company and any shares of
            Common Stock with respect to which the Company becomes obligated to make Awards,
            through the assumption of, or in substitution for, outstanding awards previously
            granted by an acquired entity, shall not be counted against the shares available for
            Awards under this Plan.

            
            (b)          
            Treatment of Certain Awards. Any shares of
            Common Stock subject to Awards shall be counted against the numerical limits of
            this Section 1.6 as two shares
            for every share subject thereto. For example, if an Award of restricted shares or
            performance shares (or any Award involving the receipt of actual “hard”
            shares of the Company) is made in the amount of 10,000 shares, then 20,000 shares shall
            be deducted from the then existing balance of authorized and unissued shares
            (originally set at 1,200,000 in Section 1.6(a), above) available for future issuances
            under the Plan.

            
            (c)          
            Adjustments. The number of shares of Common
            Stock covered by each outstanding Award, the number or amount of shares or units
            available for Awards under Section 1.6(a) or otherwise, the
            number or amount of shares or units that may be subject to Awards to any one Grantee
            under Section 1.7(b) or
            otherwise, the price per share of Common Stock or units covered by each such
            outstanding Award and any other calculation relating to shares of Common Stock
            available for Awards or under outstanding Awards (including Awards under
            Section 2.13) shall be
            proportionately 

             

            
            7

             

            
            

            

            

            

            
            adjusted, in order to prevent dilution or enlargement of the benefits or
            potential benefits intended to be made available under the Plan, for any increase or
            decrease in the number of issued shares of Common Stock resulting from a stock split,
            reverse stock split, stock dividend, recapitalization, combination or reclassification
            of the Common Stock or similar transaction, or any other increase or decrease in the
            number of issued shares of Common Stock effected without receipt of consideration by
            the Company or to reflect any distributions to holders of Common Stock (including
            rights offerings) other than regular cash dividends; provided, however, that conversion
            of any convertible securities of the Company shall not be deemed to have been
            “effected without receipt of consideration.” Except as expressly provided
            herein, no issuance by the Company of shares of stock of any class, or securities
            convertible into shares of stock of any class, shall affect, and no adjustment by
            reason thereof shall be made with respect to, the number or price of shares of Common
            Stock subject to an Award. After any adjustment made pursuant to this paragraph, the
            number of shares subject to each outstanding Award shall be rounded to the nearest
            whole number.

            
            (d)          
            Grants Exceeding Allotted Shares. If the
            shares of Common Stock covered by an Award exceeds, as of the date of grant, the number
            of shares of Common Stock which may be issued under the Plan without additional
            shareholder approval, such Award shall be void.

            
                	
                             

                        	
                            
                            1.7

                        	
                            
                            Regulatory
                            Considerations.

                        

            

            
            (a)          
            General. To the extent that the Board
            determines it desirable for any Award to be given any particular tax, accounting, legal
            or regulatory treatment, the Award may be made by the Board, subject to any necessary
            restrictions, conditions or other terms or otherwise in such manner as is necessary to
            obtain the desired treatment.

            
            (b)          
            Code Section 162(m) Provisions. For
            purposes of qualifying any compensation attributable to a grant of an Award to a Key
            Executive as “performance-based compensation” within the meaning of
            Section 162(m) of the Code:

            
                	
                             

                        	
                            
                            (i)

                        	
                            
                            The compensation shall either:

                        

            

            
            (A)     
            Be attributable solely to (I) Incentive Stock Options, (II) nonqualified
            stock options with a per share exercise price equal to at least 100% of the Fair Market
            Value of a share of Common Stock on the date the option is granted, and/or (III) stock
            appreciation rights for which the amount of compensation is based solely on an increase
            in the value of the shares of Common Stock of the Company after the date of grant of
            the Award; or

            
            (B)     To the extent subsection (A) above is not applicable, be based upon the
            achievement of Performance Goals established by the Committee in writing not later than
            90 days after the commencement of the period of service to which the Performance Goal
            relates, provided that the outcome is substantially uncertain at the time the Committee
            actually

             

            
            8

             

            
            

            

            

            
            establishes the Performance Goal and less than 25% of the period of
            service to which the Performance Goal relates has elapsed at such time;

            
            (ii)          
            The Committee described in Section
            1.3(a)(i) of this Plan shall grant the Award and establish
            any applicable Performance Goals;

            
            (iii)         
            With respect to any Award of stock options and/or stock appreciation
            rights described in Section 1.7(b)(i)(A)
            above (subject to Section
            1.6(b)), no Key Executive shall be granted, in any fiscal
            year, stock options, or stock appreciation rights to purchase (or obtain the benefits
            of the equivalent of) more than 200,000 shares of Common Stock (the
            “Annual Share
            Limit”);
            provided,
            however, that in connection with his or her
            initial service, the Key Executive may be granted stock options, or stock appreciation
            rights to purchase up to an additional 300,000 (the
            “Initial Service Limit”)
            shares of Common Stock of the Company which do not count against the Annual Share
            Limit; and provided,
            further, that if a stock option, or stock
            appreciation right is cancelled in the same fiscal year of the Company in which it was
            granted (other than in connection with a transaction described in
            Section 1.6(c)), the cancelled stock
            option, or stock appreciation right will be counted against the Annual Share Limit for
            such fiscal year (for this purpose, if the exercise price of a stock option is reduced,
            the transaction will be treated as a cancellation of the stock option and grant of a
            new stock option). The foregoing Annual Share Limit and Initial Service Limit shall be
            adjusted proportionately in connection with any change in the Company’s
            capitalization as described in Section
            1.6(c). All provisions of this
            Section 1.7(b)(iii) will also apply to
            grants of full value shares, including restricted stock, restricted units and
            performance shares, except that the maximum grants will be fifty percent (50%) of the
            maximums shown above applicable to stock options and stock appreciation rights. Nothing
            in this Section 1.7(b)(iii) or elsewhere in this Plan shall be construed so as to
            permit, without prior stockholder approval, the administrator of the Plan to reprice
            stock options, stock appreciation or purchase rights, outstanding under the Plan by
            modifying or amending such options or rights or canceling such options or rights and
            replacing them with new options or rights having a lower exercise price.

            
            (iv)          
            No Key Executive shall be paid, in any fiscal year, more than $2,000,000
            in cash performance units (which are a separate vehicle from performance shares);
            and

            
            (v)          
            Prior to payment of the compensation, the Committee described in
            Section 1.3(a)(i) certifies that any
            applicable Performance Goals and any other material terms of the Award were in fact
            satisfied.

             

            
            9

             

            
            

            ARTICLE II

            AWARDS UNDER THE PLAN

            
            2.1          
            Awards and Award Agreements. Each Award
            granted under the Plan shall be evidenced by an Award Agreement which shall contain
            such provisions as the Board in its discretion deems necessary or desirable. For any
            awards of stock rights that would be subject to the provisions of section 409A of the
            Code, each such Award shall include a provision fixing the number of shares covered by
            the Award. Such provisions may further include (but are not limited to) restrictions on
            the Grantee’s right to transfer the shares of Common Stock issuable pursuant to
            the Award, a requirement that the Grantee become a party to an agreement restricting
            transfer or allowing repurchase of any shares of Common Stock acquired pursuant to the
            Award, a requirement that the Grantee acknowledge that such shares are acquired for
            investment purposes only, and a right of first refusal exercisable by the Company in
            the event that the Grantee wishes to transfer any such shares. The Board may grant
            Awards in tandem or in connection with or independently of or in substitution for any
            other Award or Awards granted under this Plan or any award granted under any other plan
            of the Company. Payments or transfers to be made by the Company upon the grant,
            exercise or payment of an Award may be made in such form as the Board shall determine,
            including cash, shares of Common Stock or other securities (or proceeds from the sale
            thereof), other Awards (by surrender or cancellation thereof or otherwise) or other
            property and may be made in a single payment or transfer, in installments or on a
            deferred basis. The Board may determine that a Grantee shall have no rights with
            respect to an Award unless such Grantee accepts the Award within such period as the
            Board shall specify by executing an Award Agreement in such form as the Board shall
            determine and, if the Board shall so require, makes payment to the Company in such
            amount as the Board may determine. Loans to executive officers of the Company may not
            be extended, guaranteed or arranged by the Company in violation of Section 402 of
            the Sarbanes-Oxley Act of 2002, Regulation O of the Board of Governors of the Federal
            Reserve System or any other applicable law or regulation.

            
            2.2          
            No Rights as a Shareholder. No Grantee of
            an Award (or other person having rights pursuant to such Award) shall have any of the
            rights of a shareholder of the Company with respect to shares subject to such Award
            until the transfer of such shares to such person. Except as otherwise provided
            in Section 1.6(c), no
            adjustment shall be made for dividends, distributions or other rights (whether ordinary
            or extraordinary, and whether in cash, securities or other property) for which the
            record date is prior to the date such shares are issued.

            
                	
                             

                        	
                            
                            2.3

                        	
                            
                            Grant of Stock Options, Stock Appreciation Rights and
                            Additional Options.

                        

            

            
            (a)          
            Grant of Stock Options. The Board may grant
            stock options, including Incentive Stock Options and nonqualified stock options, to
            purchase shares of Common Stock from the Company, to such Key Persons, in such amounts
            and subject to such terms and conditions (including the attainment of Performance
            Goals), as the Board shall determine in its discretion, subject to the provisions of
            the Plan.

            
            (b)          
            Grant of Stock Appreciation Rights. The
            Board may grant stock appreciation rights to such Key Persons, in such amounts and
            subject to such terms and conditions (including the attainment of Performance Goals),
            as the Board shall determine in its discretion, subject to the provisions of the Plan.
            Stock appreciation rights may be granted in connection with all or any part of, or
            independently of, any stock option granted under the Plan. A stock appreciation right
            may be granted at or after the time of grant of such option.

            
             

            
            10

             

            
            

            

            

            
            

            
             

            
            (c)          
            Stock Appreciation Rights. The Grantee of a
            stock appreciation right shall have the right, subject to the terms of the Plan and the
            applicable Award Agreement, to receive from the Company an amount equal to (i) the
            excess of the Fair Market Value of a share of Common Stock on the date of exercise of
            the stock appreciation right over (ii) the exercise price of such right as set
            forth in the Award Agreement (if the stock appreciation right is granted in connection
            with a stock option, then the exercise price of the option), multiplied by (iii) the
            number of shares with respect to which the stock appreciation right is exercised.
            Payment to the Grantee upon exercise of a stock appreciation right shall be made in
            cash or in shares of Common Stock (valued at their Fair Market Value on the date of
            exercise of the stock appreciation right) or both, as the Board shall determine in its
            discretion. Upon the exercise of a stock appreciation right granted in connection with
            a stock option, the number of shares subject to the option shall be correspondingly
            reduced by the number of shares with respect to which the stock appreciation right is
            exercised. Upon the exercise of a stock option in connection with which a stock
            appreciation right has been granted, the number of shares subject to the stock
            appreciation right shall be reduced correspondingly by the number of shares with
            respect to which the option is exercised.

            
            (d)          
            Exercise Price. Each Award Agreement with
            respect to a stock option or stock appreciation right shall set forth the exercise
            price, which shall be determined by the Committee in its discretion, except that no
            stock option or stock appreciation right may be granted with an exercise price below
            the fair market value of the Company’s common stock on the date of
            grant.

            
            (e)          
            Exercise Periods. Each Award Agreement with
            respect to a stock option or stock appreciation right shall set forth the periods
            during which the Award evidenced thereby shall be exercisable, and, if applicable, the
            conditions which must be satisfied (including the attainment of Performance Goals) in
            order for the Award evidenced thereby to be exercisable, whether in whole or in part.
            Such periods and conditions shall be determined by the Board in its discretion;
            provided,
            however, that no stock option or stock
            appreciation right shall be exercisable more than ten (10) years after the date the
            Award is issued.

            
            (f)           
            Incentive Stock Options.
            Notwithstanding Section 2.3(d) and
            (e), with respect to any Incentive Stock Option or stock
            appreciation right granted in connection with an Incentive Stock Option (i) the
            exercise price shall be at least 100% of the Fair Market Value of a share of Common
            Stock on the date the option is granted (except as permitted in connection with the
            assumption or issuance of options in a transaction to which Section 424(a) of the
            Code applies) and (ii) the exercise period shall not be for longer than ten (10) years
            after the date of the grant. To the extent that the aggregate Fair Market Value
            (determined as of the time the option is granted) of the shares of Common Stock with
            respect to which Incentive Stock Options and stock appreciation rights granted in
            connection with Incentive Stock Options granted under this Plan and all other plans of
            the Company are first exercisable by any Grantee during any calendar year shall exceed
            the maximum limit (currently, $100,000), if any, imposed from time to time under
            Section 422 of the Code, such options and rightsshall be treated as nonqualified
            stock

            
             

            
            11

             

            
            

            

            

            

            
            options. For purposes of this
            Section 2.3(f), Incentive Stock
            Options shall be taken into account in the order in which they were granted.

            
            (g)          
            Ten Percent Owners. Notwithstanding the
            provisions of Sections 2.3(d), (e)
            and (f), to the extent required under Section 422 of the Code, an Incentive Stock
            Option may not be granted under the Plan to an individual who, at the time the option
            is granted, owns stock possessing more than 10% of the total combined voting power of
            all classes of stock of his or her employer corporation or of its parent or subsidiary
            corporations (as such ownership may be determined for purposes of
            Section 422(b)(6) of the Code) unless (i) at the time such Incentive Stock Option
            is granted the exercise price is at least 110% of the Fair Market Value of the shares
            subject thereto, and (ii) the Incentive Stock Option by its terms is not exercisable
            after the expiration of five (5) years from the date granted.

            
            (h)          
            Repricing Requires Shareholder Approval.
            Except as allowed by Section 3.1(e) of this Plan (with regard to modifications in order
            to avoid tax treatment under section 409A of the Code), no Award granted hereunder
            shall have its exercise price modified or “repriced” without first
            obtaining shareholder approval.

            
            2.4          
            Exercise of Stock Options and Stock Appreciation
            Rights. Each stock option or stock appreciation right granted
            under the Plan shall be exercisable as follows:

            
            (a)          
            Exercise Period. A stock option or stock
            appreciation right shall become and cease to be exercisable at such time or times as
            determined by the Board and set forth in the Award Agreement, except that in no event
            shall a stock option or stock appreciation right be extended beyond the initial option
            term at a time when the fair market value of the stock underlying the option is greater
            than the Exercise Price unless such extension remains within ten (10) years from the
            initial date of grant.

            
            (b)          
            Manner of Exercise. Unless the applicable
            Award Agreement otherwise provides, a stock option or stock appreciation right may be
            exercised from time to time as to all or part of the shares as to which such Award is
            then exercisable (but, in any event, only for whole shares). A stock appreciation right
            granted in connection with an option may be exercised at any time when, and to the same
            extent that, the related option may be exercised. A stock option or stock appreciation
            right shall be exercised by written notice to the Company, on such form and in such
            manner as the Board shall prescribe.

            
            (c)          
            Payment of Exercise Price. Any written
            notice of exercise of a stock option shall be accompanied by payment of the exercise
            price for the shares being purchased. Such payment shall be made (i) in cash (by
            certified check or as otherwise permitted by the Board), or (ii) (A) by
            delivery of shares of Common Stock (which, if acquired pursuant to the exercise of a
            stock option or under an Award made under this Plan or any other compensatory plan of
            the Company, were acquired at least six (6) months prior to the option exercise date)
            having a Fair Market Value (determined as of the exercise date) equal to all or part of
            the exercise price and cash for any remaining portion of the exercise price, (B) by
            cashless exercise procedure through a broker-dealer,

            
             

            
            12

             

            
            

            

            

            
            and (C) to the extent permitted by law, by such other method not
            otherwise prohibited by the Board including, without limitation, a “net
            exercise.”

            
            (d)          
            Delivery of Shares. Promptly after
            receiving payment of the full exercise price, or after receiving notice of the exercise
            of a stock appreciation right for which payment by the Company will be made partly or
            entirely in shares of Common Stock, the Company shall, subject to the provisions
            of Section 3.3 (relating to
            certain restrictions), transfer to the Grantee or to such other person as may then have
            the right to exercise the Award, the shares of Common Stock for which the Award has
            been exercised and to which the Grantee is entitled. If the method of payment employed
            upon option exercise so requires, and if applicable law permits, a Grantee may direct
            the Company to deliver the shares to the Grantee’s broker-dealer.

            
                	
                             

                        	
                            
                            2.5

                        	
                            
                            Termination of
                            Employment.

                        

            

            
            (a)          
            Termination of Employment by Grantee for any Reason or By the Company
            for Cause. Except to the extent otherwise provided in
            paragraphs (b), (c), (d) and (e) below or in the applicable Award Agreement, all
            unvested stock options and stock appreciation rights to the extent not theretofore
            exercised shall terminate immediately upon (i) the Grantee’s Termination of
            Employment at Grantee’s election for any reason or (ii) Grantee’s
            Termination of Employment by the Company for Cause.

            
            (b)          
            At Election of Company or a Related Entity.
            Except to the extent otherwise provided in the applicable Award Agreement, upon the
            Termination of Employment of a Grantee at the election of the Company or a Related
            Entity (other than in circumstances governed by paragraph (a) above or paragraphs (c),
            (d) or (e) below) the Grantee may exercise any outstanding stock option or stock
            appreciation right on the following terms and conditions: (i) exercise may be made only
            to the extent that the Grantee was entitled to exercise the Award on the date of the
            Termination of Employment; and (ii) exercise must occur within three (3) months
            after the Termination of Employment but in no event after the expiration date of the
            Award as set forth in the Award Agreement.

            
             (c)               
            Retirement.  At such time as the Company adopts a policy of retirement and
            during the continued effectiveness of such policy, except to the extent otherwise
            provided in the applicable Award Agreement, upon the Termination of Employment of a
            Grantee by reason of the Grantee’s Retirement, the Grantee may exercise any
            outstanding stock option or stock appreciation right on the following terms and
            conditions: (i) exercise may be made only to the extent that the Grantee was entitled
            to exercise the Award on the date of Retirement; and (ii) exercise must occur within
            three (3) years after Retirement but in no event after the expiration date of the Award
            as set forth in the Award Agreement.

            
            (d)          
            Disability. Except to
            the extent otherwise provided in the applicable Award Agreement, upon the termination
            of Employment of a Grantee by reason of Disability the Grantee may exercise any
            outstanding stock option or stock appreciation right on the following terms and
            conditions: (i) exercise may be made only to the extent

            
             

            
            13

             

            
            

            

            

            
                that the Grantee was entitled to exercise the
                Award on the date of Termination of Employment; and (ii) exercise must occur no
                later than six (6) months after the Termination of Employment but in no event after
                the expiration date of the Award as set forth in the Award Agreement.

            

            
            (e)          
            Death. Except to the extent otherwise
            provided in the applicable Award Agreement, if a Grantee dies during the period in
            which the Grantee’s stock options or stock appreciation rights are exercisable,
            whether pursuant to their terms or pursuant to paragraph (b), (c) or (d) above, any
            outstanding stock option or stock appreciation right shall be exercisable on the
            following terms and conditions: (i) exercise may be made only to the extent that
            the Grantee was entitled to exercise the Award on the date of death; and
            (ii) exercise must occur no later than six (6) months after the date of the
            Grantee’s death. Any such exercise of an Award following a Grantee’s death
            shall be made only by the Grantee’s executor or administrator, unless the
            Grantee’s will specifically disposes of such Award, in which case such exercise
            shall be made only by the recipient of such specific disposition. If a Grantee’s
            executor (or administrator) or the recipient of a specific disposition under the
            Grantee’s will shall be entitled to exercise any Award pursuant to the preceding
            sentence, such executor (or administrator) or recipient shall be bound by all the terms
            and conditions of the Plan and the applicable Award Agreement which would have applied
            to the Grantee.

            
                	
                             

                        	
                            
                            2.6

                        	
                            
                            Grant of Restricted Stock and Unrestricted
                            Stock.

                        

            

            
            (a)          
            Grant of Restricted Stock. The Board may
            grant restricted shares of Common Stock to such Key Persons, in such amounts and
            subject to such terms and conditions (including the attainment of Performance Goals),
            as the Board shall determine in its discretion, subject to the provisions of the
            Plan.

            
            (b)          
            Grant of Unrestricted Stock. The Board may
            grant unrestricted shares of Common Stock to such Key Persons, in such amounts and
            subject to such terms and conditions as the Board shall determine in its discretion,
            subject to the provisions of the Plan.

            
                (c)            
            Rights as Shareholder. The Company may issue in the Grantee’s name shares
            of Common Stock covered by an Award of restricted stock or unrestricted stock. Upon the
            issuance of such shares, the Grantee shall have the rights of a shareholder with
            respect to the restricted stock or unrestricted stock, subject to the transfer
            restrictions and the Company’s repurchase rights described in paragraphs (d)
            and (e) below and to such other restrictions and conditions as the Board in its
            discretion may include in the applicable Award Agreement.

            
            (d)          
            Company to Hold Certificates. Unless the
            Board shall otherwise determine, any certificate issued evidencing shares of restricted
            stock shall remain in the possession of the Company until such shares are free of any
            restrictions specified in the Plan or the applicable Award Agreement.

            
             

            

            
            14

             

            
            

            

            

            
                       
            (e)          
            Nontransferable. Shares of restricted stock
            may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of
            except as specifically provided in this Plan or the applicable Award Agreement. The
            Board at the time of grant shall specify the date or dates (which may depend upon or be
            related to the attainment of Performance Goals) and other conditions on which the
            non-transferability of the restricted stock shall lapse. Unless the applicable Award
            Agreement provides otherwise, additional shares of Common Stock or other property
            distributed to the Grantee in respect of shares of restricted stock, as dividends or
            otherwise, shall be subject to the same restrictions applicable to such restricted
            stock. The Board at any time may waive or amend the transfer restrictions or other
            condition of an Award of restricted stock.

            
            (f)           
            Termination of Employment. Except to the
            extent otherwise provided in the applicable Award Agreement or unless otherwise
            determined by the Board, in the event of the Grantee’s Termination of Employment
            for any reason, shares of restricted stock that remain subject to transfer restrictions
            as of the date of such termination (and therefore are unvested) shall be forfeited and
            canceled.

            
                	
                             

                        	
                            
                            2.7

                        	
                            
                            Grant of Restricted Stock
                            Units.

                        

            

            
            (a)          
            Grant of Restricted Stock Units. The Board
            may grant Awards of restricted stock units to such Key Persons, in such amounts and
            subject to such terms and conditions (including the attainment of Performance Goals),
            as the Board shall determine in its discretion, subject to the provisions of the
            Plan.

            
            (b)          
            Vesting. The Board, at the time of grant,
            shall specify the date or dates on which the restricted stock units shall become vested
            and other conditions to vesting (including the attainment of Performance
            Goals).

            
            (c)          
            Termination of Employment. Except to the
            extent otherwise provided in the applicable Award Agreement or unless otherwise
            determined by the Board, in the event of the Grantee’s Termination of Employment
            for any reason, restricted stock units that have not vested shall be forfeited and
            canceled.

            
            

            	
                        2.8

                    	
                        
                        Grant of Performance Shares, Performance Options and
                        Performance Share Units.

                    

            

            

            
            (a)          
            Grant of Performance Shares, Options Share
            Units and Cash Performance Units. The Board may grant
            performance shares in the form of actual shares of Common Stock, performance options or
            share units over an identical number of shares of Common Stock, to such Key Persons, in
            such amounts (which may depend on the extent to which Performance Goals are attained),
            subject to the attainment of such Performance Goals and satisfaction of such other
            terms and conditions (which may include the occurrence of specified dates), as the
            Board shall determine in its discretion, subject to the provisions of the Plan. The
            Board may also grant cash performance units, which are cash awards subject to
            performance goal attainment, but which are denominated only in cash, not in stock. The
            Performance Goals and the length of the performance period applicable to any Award of
            performance shares, performance options, share units or performance units shall be
            determined by the Board. The Board shall determine in its discretion
            whether

            
            15

             

            
            

            

            

            

            
                
                     performance shares granted in the form of share units
                    shall be paid in cash, Common Stock, or a  combination of cash and Common
                    Stock.
                

            

            
            (b)          
            Company to Hold Certificates. Unless the
            Board shall otherwise determine, any certificate issued evidencing performance shares
            shall remain in the possession of the Company until such performance shares are earned
            and are free of any restrictions specified in the Plan or the applicable Award
            Agreement.

            
            (c)          
            Nontransferable. Performance shares may not
            be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except
            as specifically provided in this Plan or the applicable Award Agreement. The Board at
            the time of grant shall specify the date or dates (which may depend upon or be related
            to the attainment of Performance Goals) and other conditions on which the
            non-transferability of the performance shares shall lapse. Unless the applicable Award
            Agreement provides otherwise, additional shares of Common Stock or other property
            distributed to the Grantee in respect of performance shares, as dividends or otherwise,
            shall be subject to the same restrictions applicable to such performance shares. The
            Board at any time may waive or amend the transfer restrictions or other condition of an
            Award of performance shares.

            
            (d)          
            Termination of Employment. Except to the
            extent otherwise provided in the applicable Award Agreement or unless otherwise
            determined by the Board, in the event of the Grantee’s Termination of Employment
            for any reason, performance shares and performance share units or cash performance
            units that remain subject to transfer restrictions as of the date of such termination
            (and therefore shall not have vested) shall be forfeited and canceled.

            
            2.9          
            Grant of Dividend Equivalent Rights. The
            Board may in its discretion include in the Award Agreement with respect to any share
            denominated Award a dividend equivalent right entitling the Grantee to receive amounts
            equal to the ordinary dividends that would be paid, during the time such Award is
            outstanding and unexercised, on the shares of Common Stock covered by such Award if
            such shares were then outstanding. In the event such a provision is included in an
            Award Agreement, the Board shall determine whether such payments shall be made in cash,
            in shares of Common Stock or in another form, whether they shall be conditioned upon
            the exercise or vesting of, or the attainment or satisfaction of terms and conditions
            applicable to, the Award to which they relate, the time or times at which they shall be
            made, and such other terms and conditions as the Board shall deem
            appropriate.

            
            

            	
                         

                    	
                        
                        2.10

                    	
                        
                        Deferred Stock
                        Units.

                    

            
            (a)          
            Description. Deferred
            stock units shall consist of a restricted stock, restricted stock unit, performance
            share or share unit Award that the Board in its discretion permits to be paid out in
            installments or on a deferred basis, in accordance with rules and procedures
            established by the Board. Deferred stock units shall remain subject to the claims of
            the Company’s general creditors until distributed to the Grantee. Cash
            Performance Units may be deferred, but shall remain subject to the claims of the
            Company’s general creditors until distributed to the Grantee.

            
             

            
            16

             

            
            

            

            
           
                 
            

            
            (b)          
            162(m) Limits. Deferred stock units and
            deferred cash performance units shall be subject to the annual Section 162(m)\
            limits applicable to the underlying restricted stock, restricted stock unit,
            performance share or share unit or cash performance unit Award as forth in
            Section 1.7(b).

            
            2.11       
            Other Stock-Based Awards. The Board may
            grant other types of stock-based Awards to such Key Persons, in such amounts and
            subject to such terms and conditions, as the Board shall in its discretion determine,
            subject to the provisions of the Plan. Such Awards may entail the transfer of actual
            shares of Common Stock, or payment in cash or otherwise of amounts based on the value
            of shares of Common Stock.

            
                	
                             

                        	
                            
                            2.12

                        	
                            
                            Director Stock
                            Options.

                        

            

            
            (a)          
            Eligibility. Subject to the specific
            requirements, terms and conditions as adopted from time to time by the Board in its
            discretion (i) all voting directors of the Company who are not employees of the Company
            (“Non-Employee
            Directors”) shall receive stock options pursuant to the
            conditions of this
            Section 2.12.

            
            (b)          
            Grant of Director Stock Options. Each
            Non-Employee Director may be granted stock options to purchase shares of Common Stock
            of the Company.

            
            (c)          
            Exercise Price. Notwithstanding
            Section 2.3(d), until and unless the
            Board in its discretion determines otherwise, the per share exercise price for each
            stock option granted under this Section 2.13
            shall be 100% of the Fair Market Value of a share of Common Stock on the
            date the stock option is granted, provided that in no event shall the per share
            exercise price be less than 100% of the Fair Market Value of a share of Common Stock on
            the date the stock option is granted.

            
            (d)          
            Exercise Period. Each stock option granted
            under this Section 2.13 shall
            vest, become exercisable and possess a term in accordance with the policy then in place
            and as adopted by the Board, provided, however, that (i) if the Non-Employee
            Director’s

             

            
            17

             

            
            

            

            

            
            service on the Board is terminated as a result of not being renominated
            or reelected to the Board, then such stock option shall continue to exercisable until
            the earlier to occur of (A) the expiration of the remaining term of the option or (B)
            three (3) years from the date Board service terminated, and (ii) no stock option may
            have a term in excess of ten (10) years.

            
            (e)          
            Non-statutory Options. Stock options
            granted under this Section 2.12
            will constitute nonqualified stock options.

            
            (f)           
            Other Stock Option Terms Applicable. Except
            as set forth in this
            Section 2.12, all stock options
            granted under this Section 2.12
            will be subject to and benefited by the terms and conditions
            (including Section 3.7) of the
            Plan applicable to other stock options granted under the Plan.

            
            2.13       
            Section 409A Compliance. Nothwithstanding
            any provisions to the contrary, Awards made under this Article II that provide for the
            nonqualified deferral of compensation (including any amendments to such Awards) will
            comply with all provisions of Section 409A of the Code and the Regulations promulgated
            thereunder. No award providing for the deferral of compensation shall permit the
            acceleration of the time or schedule of any payment, except as provided in Section
            409A. Compensation deferred pursuant to such an Award with comply with all distribution
            rules of Section 409A, and shall not be distributed earlier than—

             

            
            (i) separation from service as determined by the Secretary (except as
            provided in Section 409A(B)(i), relating to deferred compensation payable to key
            employees after the termination of service),

            
             

            
            (ii) the date the participant becomes disabled (within the meaning of
            subparagraph (C) of Section 409A),

            
             

            
            (iii) death,

            
             

            
            (iv) a specified time (or pursuant to a fixed schedule) specified under
            the plan at the date of the deferral of such compensation,

            
             

            
            (v) to the extent provided by the Secretary, a change in the ownership
            or effective control of the corporation, or in the ownership of a substantial portion
            of the assets of the corporation, or

            
             

            
            (vi) the occurrence of an unforeseeable emergency (as that term is
            defined by Section 409A(a)(2)(B)(i).

            
             

            
            2.14       
            Deferral Election. To the extent to which
            any participant in this Plan is allowed to elect to defer compensation for services
            performed during a taxable year, such election shall be made not later than the close
            of the preceding taxable year, or such early deadline as proscribed in Section
            409A(a)(4) of the Code.

             

            
            18

             

            
            

            

            

            

            
            ARTICLE III

            
            MISCELLANEOUS

            
                	
                             

                        	
                            
                            3.1

                        	
                            
                            Amendment of the Plan; Modification of
                            Awards.

                        

            

            
            (a)          
            Board Authority to Amend Plan. The Board in
            its discretion may at any time suspend, discontinue, revise or amend the Plan in any
            respect whatsoever, except that any such amendment (other than an amendment pursuant to
            paragraphs (d), (e) or (f) of this Section 3.1
            or an amendment to effect an assumption or other action consistent
            with Section 3.7) that
            materially impairs the rights or materially increases the obligations of a Grantee
            under an outstanding Award shall be effective with respect to such Grantee and Award
            only with the consent of the Grantee (or, upon the Grantee’s death, the
            Grantee’s executor (or administrator) or the recipient of a specific disposition
            under the Grantee’s will).

            
            (b)          
            Shareholder Approval. Shareholder approval
            of any amendment shall be obtained to the extent necessary to comply with
            Section 422 of the Code (relating to Incentive Stock Options) or any other
            applicable law, regulation or rule (including the rules of self-regulatory
            organizations). As set forth in Section
            2.3(h), shareholder approval shall be required for any
            “repricing” of a previously granted Award hereunder.

            
            (c)          
            Board Authority to Amend Awards. Subject
            to Section 2.3(h) which requires
            shareholder approval for any “repricing” of an Award granted hereunder, the
            Board in its discretion may at any time, whether before or after the grant, expiration,
            exercise, vesting or maturity of or lapse of restriction on an Award or the Termination
            of Employment of a Grantee, amend any outstanding Award or Award Agreement, including
            an amendment which would accelerate the time or times at which the Award becomes
            unrestricted or may be exercised, or waive or amend any goals, restrictions or
            conditions set forth in the Award Agreement, provided that no Award of a stock option
            or stock appreciation right shall be amended in such a way as might, under the Section
            409A Regulations, provide for the additional deferral of compensation or an effective
            decrease in the exercise price of the Award to a price below what was the Fair Market
            Value of the Common Stock on the date of grant. Further, any such amendment (other than
            an amendment pursuant to paragraphs (d), (e) or (f) of this
            Section 3.1 or an amendment to effect
            an action consistent with
            Section 3.7) that materially impairs
            the rights or materially increases the obligations of a Grantee under an outstanding
            Award shall be made only with the consent of the Grantee (or, upon the Grantee’s
            death, the Grantee’s executor (or administrator) or the recipient of a specific
            disposition under the Grantee’s will). For purposes of the Plan, any action of
            the Board that alters or affects the tax treatment of any Award shall not be considered
            to materially impair any rights of any Grantee.

            
            (d)          
            Regulatory Changes Generally.
            Notwithstanding anything to the contrary in this Plan, the Board shall have full
            discretion to amend the Plan or an outstanding Award or Award Agreement to the extent
            necessary to preserve any tax, accounting, legal

             

            
            19

             

            
            

            

            

            
            

            
            or regulatory treatment with respect to any Award and any outstanding
            Award Agreement shall be deemed to be so amended to the same extent, without obtaining
            the consent of any Grantee (or, after the Grantee’s death, the Grantee’s
            executor (or administrator) or the recipient of a specific disposition under the
            Grantee’s will) provided that such amendment does not adversely affect a
            Grantee’s rights under the Plan or such Award and Award Agreement.

            
            (e)          
            Section 409A Changes. Notwithstanding
            anything to the contrary in this Plan, the Board shall have full discretion to amend
            the Plan or any outstanding Award or Award Agreement to the extent necessary to avoid
            the imposition of any tax under Section 409A of the Code. Any such amendments to
            the Plan, an Award or an Award Agreement may be adopted without obtaining the consent
            of any Grantee (or, after the Grantee’s death, the Grantee’s executor (or
            administrator) or the recipient of a specific disposition under the Grantee’s
            will), regardless of whether such amendment adversely affects a Grantee’s rights
            under the Plan or such Award or Award Agreement.

            
            (f)           
            Other Tax Changes. In the event that
            changes are made to Section 83(b), 162(m), 422, 409A or other applicable provision
            of the Code or the Treasury Regulations, the Board may, subject to
            Sections 3.1(a), (b) and (c), make any
            adjustments it determines in its discretion to be appropriate with respect to the Plan
            or any Award or Award Agreement.

            
                	
                             

                        	
                            
                            3.2

                        	
                            
                            Tax Withholding.

                        

            

            
            (a)          
            Tax Withholdings. As a condition to the
            receipt of any shares of Common Stock pursuant to any Award or the lifting of
            restrictions on any Award, or in connection with any other event that gives rise to a
            federal or other governmental tax withholding obligation on the part of the Company
            relating to an Award (including, without limitation, FICA tax), the Company shall be
            entitled to require that the Grantee remit to the Company an amount sufficient in the
            opinion of the Company to satisfy such withholding obligation.

            
            (b)          
            Withholding Shares. If the event giving
            rise to the withholding obligation is a transfer of shares of Common Stock, then,
            unless otherwise provided in the applicable Award Agreement,the Grantee may satisfy
            only the minimum statutory withholding obligation imposed under paragraph (a) by
            electing to have the Company withhold shares of Common Stock having a Fair Market Value
            equal to the amount of tax to be withheld. For this purpose, Fair Market Value shall be
            determined as of the date on which the amount of tax to be withheld is determined (and
            any fractional share amount shall be settled in cash).

            
                	
                             

                        	
                            
                            3.3

                        	
                            
                            Restrictions.

                        

            

            
            (a)          
            Required Consents. If the Board shall at
            any time determine that any consent (as hereinafter defined) is necessary or desirable
            as a condition of, or in connection with, the granting of any Award, the issuance or
            purchase of shares of

             

            
            20

             

            
            

            

            

            
            Common Stock or other rights thereunder, or the taking of any other
            action thereunder (a “Plan
            Action”), then no such Plan Action shall be taken, in
            whole or in part, unless and until such consent shall have been effected or obtained to
            the full satisfaction of the Board.

            
            (b)          
            Definition. The term
            “consent” as used herein
            with respect to any action referred to in paragraph (a) means (i) any and all
            listings, registrations or qualifications in respect thereof upon any securities
            exchange or under any federal, state or local law, rule or regulation, (ii) any
            and all written agreements and representations by the Grantee with respect to the
            disposition of shares, or with respect to any other matter, which the Board shall deem
            necessary or desirable to comply with the terms of any such listing, registration or
            qualification or to obtain an exemption from the requirement that any such listing,
            qualification or registration be made, (iii) any and all consents, clearances and
            approvals in respect of a Plan Action by any governmental or other regulatory bodies,
            and (iv) any and all consents or authorizations required to comply with, or required to
            be obtained under, applicable local law or otherwise required by the Board. Nothing
            herein shall require the Company to list, register or qualify the shares of Common
            Stock on any securities exchange.

            
                	
                             

                        	
                            
                            3.4

                        	
                            
                            Nonassignability.

                        

            

            
            (a)          
            Nonassignability. No Award or right granted
            to any person under the Plan shall be assignable or transferable other than by will or
            by the laws of descent and distribution, and all such Awards and rights shall be
            exercisable during the life of the Grantee only by the Grantee or the Grantee’s
            legal representative and any such attempted assignment, transfer or exercise in
            contravention of this Section 3.4
            shall be void. Notwithstanding the foregoing, the Board may in its
            discretion permit the donative transfer of any Award under the Plan (other than an
            Incentive Stock Option) by the Grantee (including to a trust or similar instrument),
            subject to such terms and conditions as may be established by the Board.

            
            (b)          
            Cashless Exercises Permitted. The
            restrictions on exercise and transfer in paragraph (a) above shall not be deemed to
            prohibit “cashless exercise” procedures with parties who provide financing
            for the purpose of (or who otherwise facilitate) the exercise of Awards consistent with
            applicable legal restrictions and Rule 16b-3 and as otherwise permitted by
            Section 2.4(c).

            
            3.5          
            Requirement of Notification of Election Under Section 83(b) of
            the Code. If a Grantee, in connection with the acquisition of
            shares of Common Stock under the Plan, is permitted under the terms of the Award
            Agreement to make the election permitted under Section 83(b) of the Code (i.e., an
            election to include in gross income in the year of transfer the amounts specified in
            Section 83(b) of the Code notwithstanding the continuing transfer restrictions)
            and the Grantee makes such an election, the Grantee shall notify the Company of such
            election within ten (10) days of filing notice of the election with the Internal
            Revenue Service, in addition to any filing and notification required pursuant to
            regulations issued under Section 83(b) of the Code.

             

            
            21

             

            
            

            

            

            

            
            3.6          
            Requirement of Notification Upon Disqualifying Disposition Under
            Section 421(b) of the Code. If any Grantee shall make
            any disposition of shares of Common Stock issued pursuant to the exercise of an
            Incentive Stock Option under the circumstances described in Section 421(b) of the
            Code (relating to certain disqualifying dispositions), such Grantee shall notify the
            Company of such disposition within ten (10) days thereof.

            
                	
                             

                        	
                            
                            3.7

                        	
                            
                            Change in
                            Control.

                        

            

            
            (a)          
            Definition. A
            “Change in Control”
            means the occurrence of any one of the following events:

            
            (i)           
            any Person (as defined in Sections 13(d) and 14(d) of the Exchange Act)
            is or becomes the Beneficial Owner (as defined in Rule 13d-3 under the Exchange Act),
            directly or indirectly, of securities of the Company representing in excess of fifty
            percent (50%) or more of the combined voting power of the Company’s then
            outstanding securities (“Company Voting
            Securities”);
            provided,
            however, that the event described in this
            clause (i) shall not be deemed a Change in Control by virtue of any of the following
            acquisitions: (A) by the Company or any corporation controlled by the Company, (B) by
            any employee benefit plan (or related trust) sponsored or maintained by the Company or
            any corporation controlled by the Company, (C) by any underwriter temporarily holding
            securities pursuant to an offering of such securities, (D) pursuant to a Non-Qualifying
            Transaction (as defined in clause (iii) below), (E) pursuant to any acquisition by
            Grantee or any group of persons including Grantee (or any entity controlled by Grantee
            or any group of persons including Grantee), (F) a transaction (other than one described
            in clause (iii) below) in which outstanding Company Voting Securities are acquired from
            the Company, if a majority of the Continuing Directors (as defined in clause (ii)
            below) approve a resolution providing expressly that the acquisition pursuant to this
            subclause (F) does not constitute a Change in Control under this clause (F), or (G) any
            increase in the ownership position of a person of the outstanding Company Voting
            Securities as a result of an acquisition of common stock of the Company by the Company
            which, by reducing the number of shares of common stock of the Company outstanding,
            increases the proportionate number of shares beneficially owned by such person to in
            excess of fifty percent (50%)or more of the outstanding Company Voting
            Securities, provided,
            however, that if a person shall become the
            beneficial owner of in excess of fifty percent (50%) or more of the outstanding Company
            Voting Securities by reason of a share acquisition by the Company as described above
            and shall, after such share acquisition by the Company, become the beneficial owner of
            any additional shares of common stock of the Company, then such acquisition shall
            constitute a Change in Control;

            
            (ii)          
            the consummation of a merger, consolidation, statutory share exchange or
            similar form of corporate transaction involving the Company or any of its subsidiaries
            that requires the approval of the Company’s shareholders,

             

            
            22

             

            
            

            

            

            

            
            whether for such transaction or the issuance of securities in the
            transaction (a “Business
            Combination”), unless immediately following such
            Business Combination: (A) more than 50% of the total voting power of (x) the
            corporation resulting from such Business Combination (the
            “Surviving
            Corporation”), or (y) if applicable, the ultimate
            parent corporation that directly or indirectly has beneficial ownership of at least 95%
            of the voting securities eligible to elect directors of the Surviving Corporation (the
            “Parent Corporation”),
            is represented by Company Voting Securities that were outstanding immediately prior to
            such Business Combination (or, if applicable, is represented by shares into which such
            Company Voting Securities were converted pursuant to such Business Combination), and
            such voting power among the holders thereof is in substantially the same proportion as
            the voting power of such Company Voting Securities among the holders thereof
            immediately prior to the Business Combination, (B) no person (other than any
            employee benefit plan (or related trust) sponsored or maintained by the Surviving
            Corporation or the Parent Corporation), is or becomes the beneficial owner, directly or
            indirectly, of in excess of fifty percent (50%) or more of the total voting power of
            the outstanding voting securities eligible to elect directors of the Parent Corporation
            (or, if there is no Parent Corporation, the Surviving Corporation) and (C) at
            least a majority of the members of the board of directors of the Parent Corporation
            (or, if there is no Parent Corporation, the Surviving Corporation) following the
            consummation of the Business Combination are Continuing Directors (any Business
            Combination which satisfies all of the criteria specified in subclauses (A), (B) and
            (C) above shall be deemed to be a “Non-Qualifying
            Transaction”); provided,
            however, that if Continuing Directors constitute a majority
            of the Board immediately following the occurrence of a Business Combination, then a
            majority of Continuing Directors in office prior to the Consummation of the Business
            Combination may approve a resolution providing expressly that such Business Combination
            does not constitute a Change in Control under this clause (ii) for any and all purposes
            of the Plan.

            
            (iii)        
            the shareholders of the Company approve a plan of complete liquidation
            or dissolution of the Company;

            
            (iv)         
            the consummation of an agreement (or agreements) providing for the sale
            or disposition by the Company of all or substantially all of the Company’s assets
            other than a sale or disposition which would result in the voting securities of the
            Company outstanding immediately prior thereto continuing to represent 50% or more of
            the combined voting power of the Company or such surviving entity outstanding
            immediately after such sale or disposition; or

            
            (v)           
            in the case of directors, officers or employees who are entitled to the
            benefits of a change in control agreement or similar provisions within an agreement
            entered into by the Company or a Related Entity that defines or addresses change of
            control, “change of control” as defined in such agreement

             

            
            23

             

            
            

            

            

            

            
            (b)          
            Effect of Change in Control. Upon the
            occurrence of a Change in Control specified in paragraph (a)(i) above and immediately
            prior to the occurrence of a Change in Control specified in paragraph (a)(ii), (a)(iii)
            or (a)(iv) above, Awards shall Fully Vest (as defined in paragraph (c) below). If,
            within two (2) years after the occurrence of a Change in Control a Termination of
            Employment occurs with respect to any Grantee for any reason other than Cause,
            Disability, death or Retirement, Grantee shall be entitled to exercise Awards at any
            time thereafter until the earlier of (i) the date twelve (12) months after the date of
            Termination of Employment and (ii) the expiration date in the applicable Award
            Agreement.

            
            (c)          
            Fully Vest. The following shall occur if
            Awards “Fully Vest”: (i) any stock options and stock appreciation
            rights granted under the Plan shall become fully vested and immediately exercisable,
            (ii) any restricted stock, restricted stock units, performance shares, performance
            units and other stock-based Awards granted under the Plan will become fully vested and
            matured, any restrictions applicable to such Awards shall lapse and such Awards
            denominated in stock will be immediately paid out, and (iii) any Performance Goals
            applicable to Awards will be deemed to be fully satisfied;
            provided that (A) any Performance Goals
            whose performance period has not yet lapsed shall be calculated based on the higher of
            (x) the target value of the Awards as established by the Board and (y) the value of the
            Awards calculated under the terms of the Awards based on the average performance
            through the end of the fiscal quarter immediately prior to the effective date of the
            Change of Control (continued pro forma through the end of the performance period if
            necessary for purposes of determining whether the Performance Goal would have been
            met), and (B) if the Award has a performance period greater than one (1) year, the
            amount of the Award payable to the Grantee will be pro rated, based on a fraction, the
            numerator of which is the number of fiscal quarters completed from the beginning of the
            performance period until the effective date of the Change of Control and the
            denominator is the total number of fiscal quarters in the performance
            period.

            
            (d)          
            Section 409A. To the extent it is
            necessary for the term “change of control” to be defined in order for
            compensation provided under any Award to avoid the imposition of taxes under
            Section 409A of the Code, then the term “change in control,” only
            insofar as it applies to any such Award and its treatment under Section 409A, shall be
            defined as that term is defined by Section 409A-3 of the Treasury Regulations
            promulgated under Section 409A (26 CFR § 409A-3), rather than as provided
            in Section 3.7(a), and the
            terms of Sections 3.7(b) through (c)
            shall be applied and interpreted with respect to such Section 409A
            mandated definition in such manner as the Board in its discretion determines to be
            equitable and reflect the intention of Sections 3.7(a) through
            (c).

            
            (e)          
            No Conflict with Other Agreements. The
            foregoing definition of “change of control” is applicable only to the
            matters contemplated by and set forth in this Plan and any Award agreement pursuant to
            this Plan, and shall not be controlling with respect to any other agreement between the
            Company and any third party.

             

            
            24

             

            
            

            

            

            

            
            3.8          
            No Right to Employment. Nothing in the Plan
            or in any Award Agreement shall confer upon any Grantee the right to continue in the
            employ of or association with the Company or any Related Entity or affect any right
            which the Company or Related Entity may have to terminate such employment or
            association at any time (with or without cause).

            
            3.9          
            Nature of Payments. Unless the Board
            determines at any time in its discretion, any and all grants of Awards and issuances of
            shares of Common Stock under the Plan shall constitute a special incentive payment to
            the Grantee and shall not be taken into account in computing the amount of salary or
            compensation of the Grantee for the purpose of determining any benefits under any
            pension, retirement, profit-sharing, bonus, life insurance or other benefit plan of the
            Company or under any agreement with the Grantee, unless such plan or agreement
            specifically provides otherwise.

            
            3.10       
            Non-Uniform Determinations. The
            Board’s determinations under the Plan need not be uniform and may be made by it
            selectively among persons who receive, or are eligible to receive, Awards (whether or
            not such persons are similarly situated). Without limiting the generality of the
            foregoing, the Board shall be entitled, among other things, to make non-uniform and
            selective determinations, and to enter into non-uniform and selective Award Agreements,
            as to the persons to receive Awards under the Plan, and the terms and provisions of
            Awards under the Plan.

            
            3.11       
            Other Payments or Awards. Nothing contained
            in the Plan shall be deemed in any way to limit or restrict the Company from making any
            award or payment to any person under any other plan, arrangement or understanding,
            whether now existing or hereafter in effect.

            
            3.12       
            Interpretation. The section headings
            contained herein are for the purpose of convenience only and are not intended to define
            or limit the contents of the sections. As used in the Plan, “include,”
            “includes,” and “including” are deemed to be followed by
            “without limitation” whether or not they are followed by such words or
            words of like import; except as the context requires, the singular includes the plural
            and visa versa; and references to any agreement or other document are references to
            such agreement or document as amended or supplemented from time to time. Any
            determination, interpretation or similar act to be made by the Board shall be made in
            the discretion of the Board, whether or not the applicable provisions of the Plan
            specifically refer to the Board’s discretion.

            
            3.13       
            Effective Date and Term of Plan. Unless
            sooner terminated by the Board, the Plan, including the provisions respecting the grant
            of Incentive Stock Options, shall terminate on the tenth anniversary of the adoption of
            the Plan by the Board; provided that the Plan shall continue to govern outstanding
            Awards until such Awards have been satisfied or terminated. All Awards made under the
            Plan prior to its termination shall remain in effect until such Awards have been
            satisfied or terminated in accordance with the terms and provisions of the Plan and the
            applicable Award Agreements.

             

            
            25

             

            
            

            

            

            

            
            3.14       
            Governing Law. All rights and obligations
            under the Plan shall be construed and interpreted in accordance with the laws of the
            State of California, without giving effect to principles of conflict of
            laws.

            
            3.15       
            Severability; Entire Agreement. If any of
            the provisions of this Plan or any Award Agreement is finally held to be invalid,
            illegal or unenforceable (whether in whole or in part), such provision shall be deemed
            modified to the extent, but only to the extent, of such invalidity, illegality or
            unenforceability and the remaining provisions shall not be affected thereby;
            provided,
            that if any of such provisions is finally
            held to be invalid, illegal, or unenforceable because it exceeds the maximum scope
            determined to be acceptable to permit such provision to be enforceable, such provision
            shall be deemed to be modified to the minimum extent necessary to modify such scope in
            order to make such provision enforceable hereunder. The Plan and any Award Agreements
            contain the entire agreement of the parties with respect to the subject matter thereof
            and supersede all prior agreements, promises, covenants, arrangements, communications,
            representations and warranties between them, whether written or oral, with respect to
            the subject matter thereof.

            
            3.16       
            No Third Party Beneficiaries. Except as
            expressly provided therein, neither the Plan nor any Award Agreement shall confer on
            any person other than the Company and the grantee of any Award any rights or remedies
            thereunder.

            
            3.17       
            Successors and Assigns. The terms of this
            Plan shall be binding upon and inure to the benefit of the Company and its successors
            and assigns.

            
            3.18       
            Waiver of Claims. Each Grantee of an Award
            recognizes and agrees that prior to being recommended by the Committee to the Board to
            receive an Award he or she has no right to any benefits hereunder. Accordingly, in
            consideration of the Grantee’s receipt of any Award hereunder, he or she
            expressly waives any right to contest the amount of any Award, the terms of any Award
            Agreement, any determination, action or omission hereunder or under any Award Agreement
            by the Committee, the Company or the Board, or any amendment to the Plan or any Award
            Agreement (other than an amendment to this Plan or an Award Agreement to which his or
            her consent is expressly required by the express terms of the Plan or an Award
            Agreement).

             

            
            26EXHIBIT 10.20
	 
	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE U.S. SECURITIES
              AND EXCHANGE COMMISSION (THE “SEC”). THE NON-PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT
              IS INDICATED BY A “[ * ]” AND IS SUBJECT TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL
              LABORATORIES, LTD.

      AGREEMENT

      BETWEEN

      CARACO PHARMACEUTICAL LABORATORIES LTD

      AND

      SUN PHARMACEUTICAL INDUSTRIES LIMITED

      THIS AGREEMENT, made this 19th day of January, 2007 (“Effective Date”), by and between CARACO PHARMACEUTICAL LABORATORIES
          LTD, a Michigan corporation (“Caraco”), having its Registered Office at 1150 Elijah McCoy Drive, Detroit, MI 48202, U.S.A. and SUN PHARMACEUTICAL INDUSTRIES LIMITED, an Indian corporation
          (“Sun”) having its Registered Office at SPARC, Tandalja, Vadodara 390 020 India.

      WHEREAS, Sun and Caraco each wish to enter into an agreement pursuant to which Caraco wishes to market Sun generic pharmaceutical
          products which require ANDAs in the United States of America, its territories and possessions, including Puerto Rico (the “Territory”) and Sun wishes to sell agreed products whether
          developed or under development and/or whether ANDA approved or under ANDA approval to Caraco for marketing/sale by Caraco in the Territory.

      NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto,
          intending to be legally bound, hereby agree as follows: 

	 	 
	1. 	LICENSE TO MARKET OF PRODUCTS BY SUN TO CARACO. 
	 	 
	1.1	OFFER OF THE PRODUCTS BY SUN AND ACCEPTANCE BY CARACO. The generic pharmaceutical products which require ANDAs may be offered from time
        to time for inclusion under this Agreement by Sun to Caraco for marketing, distributing, selling, using, 

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

         

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON-PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

	 	licensing by Caraco in the Territory. Caraco shall inform Sun within 30 days of such offer whether Caraco would
          be interested to market the same under this Agreement and on Caraco’s acceptance by the stipulated period of 30 days, the same products (“Products”) shall be included under this
          Agreement. However by mutual agreement between the parties to this Agreement, a separate agreement may be entered into for marketing of paragraph IV filing products.

		 
	1.2	LICENSE TO SELL PRODUCTS. During the term of this Agreement, Sun, pursuant to the terms and conditions set forth
          herein, hereby grants to Caraco the exclusive right to market, advertise, promote, distribute, sell, offer to sell, use, license and otherwise exploit the Products in the Territory (the “License”).

		 
	1.3	MANUFACTURE OF PRODUCTS. Sun shall manufacture each Product in accordance with all applicable laws and regulations
          and Current Good Manufacturing Practices (defined below), whether such Products are being manufactured in connection with the submission and seeking of approval of an ANDA or for sale to the
          public following approval of an ANDA with respect thereto. 

		 
	1.4	MARKETING AND PRICING OF PRODUCTS. Subject to any limitations imposed as a result of its financial condition, Caraco
          shall (a) use its best efforts, consistent with Caraco’s usual customary practices, to market each Product in the Territory, and provide marketing personnel and such other capabilities as
          are reasonably appropriate. Notwithstanding anything else herein to the contrary, Caraco shall have full authority to determine the methods of marketing, pricing, and selling the Products to
          its customers. [ * ].

		 
	1.5	CARACO TO OBTAIN FAIR MARKET SHARE. Caraco shall obtain its fair market share. Fair market share is considered
          an equal percentage of market share which is calculated by dividing the total share available by the amount of generic manufacturers that Caraco is competing against provided that Sun has product
          available and has gained FDA approval on the first day of launch or the day that the brand patent expires. Should Sun not provide Products on the first day of launch, then Caraco will obtain
          its fair market share by the second year of distribution in the territory, excluding products under the Narrow Therapeutic Index (NTI) category which historically are difficult to obtain share.
          Should Caraco not obtain its fair market share, Sun reserves the right to terminate this Agreement as to that particular Product.

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        2

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON- PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

	1.6	NO ACTIVITIES OUTSIDE OF THE TERRITORY. Caraco shall not make, use or sell, or grant rights to others to make,
          use or sell the Product outside the Territory without the consent of Sun.

		 
	1.7	NO ASSIGNMENT OF PRODUCTS; SHARING OF INFORMATION. Without the written consent of Sun (which may be granted
          or withheld in its sole discretion), Caraco shall not (a) grant rights to any third person, to make, use or sell the Product, whether by assignment, license, sale or other transfer; and/or (b)
          sell, assign or otherwise permit access to or use of the data supporting any ANDA for a Product, or to the ANDAs themselves, to any person or entity other than Sun, the FDA and any other governmental
          agency or body with jurisdiction.

	 	 
	2.	OBLIGATIONS OF SUN WITH RESPECT TO THE PRODUCTS.
	 	 
	2.1	CONDUCT OF TESTS AND STUDIES. For the Products agreed under this Agreement for which ANDA approval is yet
          to be applied for, Sun shall conduct, at its own expense, subject to reimbursement under Section 8 below, excluding consideration pursuant to Section 3 below, complete development, and all tests,
          including a bioequivalence study (or studies) and/or pilot studies designed to provide clinical information to assist in the development of clinical bioequivalence protocols and bioanalytic methods,
          and any clinical trials which Sun and/or Caraco deem to be reasonably necessary to enable Sun to prepare and to file with the FDA an application for an ANDA for each Product. Sun shall select
          suitable clinical research organizations to conduct any such studies and trials.

		 

		(a)	Sun shall, at its sole expense, produce quantities of any Product as necessary for use in such studies and trials.
          Such Products shall be produced in accordance with those current good manufacturing regulations established in 21 CFR Parts 210 and 211, as such sections, from time to time, may be amended or
          supplemented, or any successor provisions (“Current Good Manufacturing Practices”). 

			 
		(b)	Sun shall, in connection with its clinical studies, develop manufacturing procedures, batch records, packaging
          and labeling instructions, release specifications, and quality assurance procedures and put the procedures into an FDA accepted format. 

			 
		(c)	Caraco shall have the right, but not the obligation, to conduct audits or inspect the manufacturing facilities
          of Sun from where the Product is being supplied for the purpose of its evaluation by providing advance notice of 5 working days to Sun.

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        3

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON- PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

		(d)	Any recalls will be reimbursed by the party responsible for the recall. Reimbursement will be based on HDMA guidelines
          current at the time of the recall along with additional costs requested by our customers associated with the recall. 

			 

	2.2	PREPARATION AND SUBMISSION OF ANDAS. Sun shall complete and submit the ANDA for each Product to the FDA as promptly
          as commercially practicable, shall promptly respond to inquiries by the FDA in connection with the Product, and shall monitor and support the submission. Sun shall, when requested by Caraco,
          inform Caraco regarding the ANDA registration status for the Products. Sun shall pay all expenses in connection with such submission and monitoring for each submitted Product, including the filing
          fee and all legal and consulting fees and expenses. In any ANDA process for a Product, Sun shall: 

		 

		(a)	Identify itself as the manufacturer, and identify the packagers, labelers, and contract laboratories whose components
          or services are used in production of the Product; 

			 
		(b)	Submit methods, process and cleaning validations; 
			 
		(c)	Submit a signed certificate evidencing its compliance with Current Good Manufacturing Practices; 

			 
		(d)	Submit executed master formula and batch production and control records;
			 
		(e)	Adequately describe the precautions taken to ensure proper labeling;
			 
		(f)	Submit specifications and test methods for testing the Product during the manufacturing process; 

			 
		(g)	Submit the appropriate packaging information; 
			 
		(h)	Submit the appropriate stability information; and 
			 
		(i)	submit such other information, documentation or other matters as (1) required by applicable FDA rules or regulations,
          (2) reasonably determined by Sun or Caraco to be necessary or advisable to permit the expeditious approval of such ANDA; and/or (3) requested by the FDA. 

			 

	2.3	MANUFACTURE OF SUN ANDA PRODUCTS. Sun shall manufacture each Product in accordance with Current Good Manufacturing
          Practices, whether such Products are being manufactured in connection with the submission and seeking of approval of an ANDA or for sale to the public following approval of an ANDA with respect
          thereto. 

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        4

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON- PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 	 
	3.	CONSIDERATION. 
	 	 
	3.1	CONSIDERATION. In consideration of the marketing and distribution of the Products, Caraco shall receive 10% of
          the net selling price of the Products. In consideration of the obligations of the parties set forth in Sections 1-2, Sun shall sell each Product, and Caraco shall purchase each Product, at a
          price which is set in manner that Caraco receives 10% of the net selling price, i.e. if the net sale price of the Product by Caraco is $100 U.S., then Sun will sell the Product to Caraco at a
          net price of $90 U.S. (US $100-US $10) (the “Export Price”), subject to Section 8 herein below. The net sales price is defined as the sales price less all typical trade and cash discounts,
          returns, free goods, rebates, chargebacks, fee for service and shelf stock allowances. In the case the Product is to be sold to any specific customer at a price lower than the expected market
          price, Caraco shall obtain the approval for the same from Sun and in such situation the price to be charged by Sun shall be mutually agreed to. It is further agreed that in the case of a high
          or low margin Product, the consideration for the marketing and distribution of the Products payable to Caraco shall be agreed to by and between both the parties and the Export Price shall be
          accordingly fixed.

		 
	 	It is hereby agreed and understood by the parties that all the marketing, selling and distribution expenses for
          the sale of the Product shall be paid and born by Caraco at Caraco’s own cost.

		 
	 	[ * ].
		 
	 	[ * ].
		 
	3.2	TERMS OF PAYMENT. As consideration of Sun’s entering into this Agreement, Caraco shall make the following
          payments to Sun under the following conditions:

		 

		(a)	Reports and Payment. Caraco shall pay to Sun the Export Price of the Products purchased within sixty (60)
          days following the receipt of the product, [ * ]. Sun shall send all invoices to the attention of Caraco’s accounting department. Each payment shall be accompanied by a report in sufficient
          detail to permit confirmation of the accuracy of the payment made. 

			 

	 	Caraco shall provide a quarterly Sales Report for the Products. The report shall generally include sales details
          by customer and Product (e.g. sales value during the period, sales quantity, average sales price of the Products, average credit period 

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        5

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON-PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

	 	allowed, charge backs or any other pricing calculations, special bundling of products’ offers which Caraco
          may have with customers which may affect the sales of the Products, realization of products) Caraco further agrees to provide such other reports and/or details as may be reasonably requested
          by Sun and agreed to by Caraco.

		 

		(b)	Manner of Payment. All payments hereunder shall be payable in United States dollars, by wire transfer to
          a bank account designated by Sun unless otherwise specified in writing by Sun.

			 
		(c)	Late Payments. In the event that any payment due hereunder is not made when due, the payment shall accrue
          interest from that date due at the rate of five percent per annum; provided, however, that in no event shall such range exceed the maximum legal annual interest rate. The payment of such interest
          shall not limit Sun from exercising any other rights it may have as a consequence of the lateness of any payment.

			 
		(d)	Records. During the term of this Agreement, and for a period of a minimum of five (5) years after its expiration or termination
        (or whatever is required by applicable law or any regulatory authority), Caraco and Sun shall keep complete and accurate records in sufficient detail to permit Sun or Caraco, as the case may be,
        to confirm the accuracy of all payments due and paid hereunder.
			 
		(e)	Taxes. The parties agree that each is responsible for its own taxes attributable to this Agreement.

			 

	4.	PURCHASE FORMS. To the extent of any conflict or inconsistency between this Agreement and any purchase orders,
          purchase order releases, confirmations, acceptances and similar documents submitted by a party in conducting the activities contemplated under this Agreement, the terms of this Agreement shall
          govern.

		 
	5.	CONFIRMATION. Sun shall confirm each purchase order within seven (7) business days from the date of receipt
          of a purchase order and shall supply a Product within a maximum of sixty (60) days from the date of acceptance of a purchase order, or later if so specified in the purchase order.

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        6

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON- PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

	6.	DELIVERIES.  Delivery terms for the Product shall be prepaid by Sun or such other manufacturing facility designated
          by Sun. Sun shall ship the Products in accordance with Caraco’s purchase order form or as otherwise directed by Caraco in writing. Title to any Products purchased by Caraco shall pass to
          Caraco upon the delivery of such Product to Caraco.

		 
	7.	FORECASTS. Not later than four (4) months prior to the anticipated date of commercialization of a particular Product
          in the Territory, Caraco will provide Sun with a twelve (12) month forecast of Caraco’s requirements of that Product. On an ongoing basis, twelve (12) month rolling forecasts shall be provided
          quarterly, no less than thirty (30) days prior to the beginning of each quarter. Said requirements will be based on standard production planning parameters including but not limited to sales
          forecasts, sales `demand forecasts, promotional forecasts, inventory requirements, and the like. The first two (2) quarters of each twelve (12) month forecast will be stated in monthly requirements.
          The second two (2) quarters of each twelve (12) month forecast will be total requirement by stock keeping unit and will be stated as quarterly requirements. The first three (3) months of each
          twelve (12) month forecast will be firm orders and binding on Caraco. The second three (3) months will be allowed to be flexed from the previous forecast by plus or minus twenty-five percent
          (25%) per month until fixed by the subsequent forecast; provided that the aggregate adjustment from the quantity set forth in the previous forecast for such three (3) month period shall not exceed
          fifty percent (50%) in the aggregate during that three (3) month period. The total quantities for the last two (2) quarters of each twelve (12) month forecast will be an estimate and not binding.
          All orders will be for full batch quantities. It is understood that Sun will not maintain a Product inventory in excess of the firm portion of the forecast, but will produce a Product upon receipt
          of that portion of Caraco’s forecasts that constitute firm orders. Caraco agrees to use commercially reasonable efforts to purchase a sufficient amount of a Product to enable Caraco to carry
          sufficient inventory to allow for fluctuations in sales demand so as to allow Sun reasonable lead time to meet increased demand. Sun will use commercially reasonable efforts to meet any increase
          in demand in excess of the allowed adjustment, but will not be obligated to do so.

		 
	8.	DEVELOPMENT AND LITIGATION AND RELATED COSTS. Sun will bear all development and legal/litigation costs for the
          Products having bio-equivalency study costs of $350,000 U.S. or less. Where the bio-equivalency study costs and legal/litigation costs for the Products exceed $350,000 U.S for a Product, legal
          costs for infringement and/or other litigation along with the bio-equivalency study costs related to that Product will be apportioned in such proportion as may be mutually agreed,on product
          to product basis, by both the parties to this Agreement. Sun shall provide Caraco with copies of all legal and other 

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        7

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON- PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

	 	relevant bio-equivalency study invoices; pay the fees in full and bill Caraco for its agreed proportionate share.
          When the offer to market any Product, at the sole discretion of Sun, is made by Sun to Caraco under this Agreement, Caraco has the responsibility to assess the potential litigation costs
          prior to accepting to market the product.

	 	 
	9.	REPRESENTATIONS AND WARRANTIES OF SUN. 
	 	 
	 	Sun, as an inducement to Caraco to enter into this Agreement, represents, warrants and covenants to Caraco as follows: 

		 
	9.1	RIGHTS TO PROPRIETARY TECHNOLOGICAL INFORMATION. Sun will have at the time a Product is delivered to Caraco, the
          full right, power and authority to grant the exclusive License to the Products, and intellectual property rights relating to each Product, to Caraco in the Territory pursuant to the terms of
          this Agreement to permit Caraco to perform pursuant to this Agreement and market and sell each Product free and clear of any mortgage, lien, encumbrance or any other third-party interest of any
          kind. Sun is not aware of any facts or circumstances that a Product is subject to any restriction, covenant, license (other than this Agreement) or judicial and administrative order of any kind
          which detract in any material respect from the value of the Product, or which could interfere with Caraco’s exercise of its rights in the Territory as contemplated by this Agreement.

		 
	9.2	RIGHTS TO PRODUCTS. Sun shall inform Caraco about any notice or knowledge, if any that (i) that the rights to develop,
          market and sell any of the Products have been challenged in any judicial or administrative proceeding, or (ii) any person, entity or product has infringed or will infringe any patent or other
          rights of Sun with respect to any Product, or (iii) any patent rights or other intellectual property rights, including but not limited to rights of trademark, trade and copyright have been infringed
          by Sun or will be infringed by Caraco by virtue of performing the activities contemplated by this Agreement.

		 
	9.3	RIGHT TO EXECUTE AND PERFORM. Sun has full right, power and authority to execute and deliver this Agreement, and
          to perform its obligations under it, and has taken all necessary action to authorize such execution, delivery and performance. This Agreement constitutes legal, valid and binding obligation of
          Sun enforceable against it in accordance with its terms.

		 
	9.4	COMPLIANCE WITH LAWS. Sun will comply with all applicable laws in connection with performance of its obligations
          under this Agreement. The execution, delivery and performance of this Agreement by Sun does not violate any provision of applicable law or of 

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        8

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON- PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

	 	any regulation, order decree of any court, arbitration or governmental authority, or any other agreement to which
          Sun is a party. No consents, approvals or authorizations, registrations or filings are required in connection with the execution, delivery, performance, validity or enforceability of this Agreement,
          except as have been obtained or set forth in this Agreement.

		 
	9.5	SURVIVABILITY. The foregoing representations, warranties and covenants shall survive the termination of this Agreement,
          shall be deemed to be made anew each time that a Product is delivered by Sun to Caraco, and shall not be affected by any examination made by or on behalf of Caraco, the knowledge of its officers,
          directors, stockholders, employees or agents or the acceptance of any certificate or opinion.

	 	 
	10.	REPRESENTATIONS AND WARRANTIES OF CARACO. 
	 	 
	 	As an inducement to Sun to enter into this Agreement, Caraco represents and warrants to Sun as follows: 

		 
	10.1	RIGHT TO EXECUTE AND PERFORM. Caraco has full right, power and authority to execute and deliver this Agreement,
          and to perform its obligations under it, and has taken all necessary action to authorize such execution, delivery and performance. This Agreement constitutes the legal, valid and binding obligation
          of Caraco, enforceable against it in accordance with its terms.

		 
	10.2	COMPETING PRODUCTS. During the term of this Agreement, Caraco shall not manufacture, sell, distribute or market
          the same or similar products to the Products which are subject to this Agreement, which the development list related thereto will be reviewed from time to time, from other suppliers in TERRITORY
          and the specific Product is covered under this Agreement.

		 
	10.3	COMPLIANCE WITH LAW. Caraco will comply with all applicable laws in connection with performance of its obligations
          under this Agreement. The execution, delivery and performance of this Agreement by Caraco does not and will not violate any provision of applicable law or of any regulation, order decree of any
          court, arbitration or governmental authority or any other agreement to which Caraco is a party. No consents, approvals or authorizations, registrations or filings are required in connection with
          the execution, delivery, performance, validity or enforceability of this Agreement, except as had been obtained or set forth in this Agreement.

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        9

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON- PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

	10.4 	SURVIVABILITY. The foregoing representations, warranties and covenants shall survive the termination of this Agreement,
          and shall be deemed to be made anew each time that a Product is delivered by Sun to Caraco, and shall not be affected by any examination made by or on behalf of Sun, the knowledge of its officers,
          directors, stockholders, employees or agents or the acceptance of any certificate or opinion.

	 	 
	11.	INDEMNIFICATION, INSURANCE AND LIMITATIONS OF LIABILITY. 
	 	 
	11.1	Caraco shall indemnify, defend and hold harmless, Sun, its affiliates and its stockholders, directors, officers,
          employees, advisors and agents against any and all liability, damage, loss or expenses (including reasonable fees, costs and expenses of attorneys and other professionals and court costs, but
          excluding consequential damages for lost profits) resulting from, arising out of or connected with: (a) any breach of the representations, warranties or covenants by Caraco in this Agreement,
          and/or (b) any negligence, intentional misconduct or other wrongdoing of Caraco, and/or (c) any claim by third parties relating to the distribution, promotion, use or sale of the Products by
          Caraco (except for liabilities, damages, losses or expenses which are Sun’s obligation under Section 11.2 below). These indemnification obligations shall survive the termination of this
          Agreement or the termination of any Product.

		 
	11.2	Sun shall indemnify, defend and hold harmless, Caraco, its affiliates and its stockholders, directors, officers,
          employees, advisors and agents against any and all liability, damage, loss or expenses (including reasonable fees, costs and expenses of attorneys and other professionals and court costs, but
          excluding consequential damages for lost profits) resulting from, arising out of or connected with (a) any breach of the representations, warranties or covenants by Sun in this Agreement, and/or
          (b) any negligence, intentional misconduct or other wrongdoing of Sun, and/or (c) the manufacture, operation and/or design of any Product, including all product liability claims; and/or (d) any
          claim, demand or suit alleging that any Product infringes any third party’s patent, copyright, trademark, trade secret or other intellectual property right, except when this clause is excluded
          for any Product as mutually agreed by and between Sun and Caraco. These indemnification obligations shall survive the termination of this Agreement or the termination of any Product.

		 
	11.3	Sun undertakes that it shall carry out within reasonable time of entering into this Agreement and will continue
          to carry, with insurance companies rated A- or better, the insurance coverage set forth in this Section 11.3, continuously during the term of this Agreement, and thereafter as provided herein:

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        10

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON- PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

		(a)	Commercial general liability insurance on an occurrence form containing such limits as may be mutually agreed upon
          by Sun and Caraco protecting against bodily injury, property damage and personal injury claims arising from the exposures of: (i) product liability; and (ii) contractual liability; and:

			 

		(i)	this coverage must specifically state that the insurance provided by Sun shall be considered primary and non-contributory,
          any of Caraco’s insurance shall be considered excess for the purpose of responding to claims; 

			 
		(ii)	Sun shall add Caraco as an Additional Insured on the policy by having the insurance carrier issue an Additional
          Insured Endorsement(s);

			 
		(iii)	Commercial general liability insurance coverage must be maintained for ten (10) years after the termination or
          expiration of this Agreement.

			 

		(b)	Sun must disclose all applicable insurance policy deductibles and/or self-insured retentions, and agrees to be
          liable for all costs within the deductibles and/or self-insured retentions.

			 
		(c)	Sun shall evidence that such all insurance required under this Agreement is in force by furnishing Caraco with
          a Certificate of Insurance, or if requested by Caraco, certified copies of the insurance policies. Any attempt by Sun to cancel or modify any insurance coverage, or any failure by Sun to maintain
          such insurance coverage, shall be a default under this Agreement and, upon such default, Caraco will have the right to terminate this Agreement and/or exercise any of its rights at law or at
          equity unless the same has arisen due to non reimbursement by Caraco of insurance expenses incurred by Sun for the for the Products under this Agreement pursuant to Section 3.1 of this Agreement.
          In addition to any other remedies, Caraco may, at its discretion, withhold payment of any sums due under this Agreement until Sun provides adequate proof of insurance.

			 

	11.4	Except as expressly provided herein, in no event shall either party be liable to the other party in connection
          with this Agreement and/or the Products, regardless of the form of action or theory of recovery, for any: (a) indirect, special, exemplary, consequential, incidental or punitive damages, even
          if that party has been advised of the possibility of such damages; and/or (b) lost profits, lost revenues, lost business expectancy, business interruption losses and/or benefit of the bargain
          damages. The limitations set forth in Sections 11.4(a) and (b) do not apply to any liability or amounts related to or arising from a party’s indemnification 

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        11

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON- PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

	 	obligations under this Agreement and/or a party’s breach of its confidentiality obligations under this Agreement.

	 	 
	12. 	TERM AND TERMINATION 
	 	 
	12.1	TERM. The initial term of this Agreement shall be three (3) years from the Effective Date except that to the extent
          the License period for a Product is less than 3 years, this Agreement shall be effective for each such Product until completion of 3 years from the date of launch of that Product in the Territory.
          The License granted with respect to any Product delivered by Sun to Caraco and as to which Caraco and Sun have fulfilled their obligations, shall continue until the expiration or termination
          of this Agreement. Prior to 90 days of the expiration date of the Agreement either party may request a 1 year extension of the Agreement with no material changes and/or or a renewal of another
          3 year agreement after an economics review, which will be mutually agreed upon by both parties in writing. Should the parties not agree to extend this Agreement, then this Agreement will end
          at midnight EST on the 3rd anniversary date of this Agreement.

		 
	12.2	TERMINATION. At any time, this Agreement may be terminated in its entirety or with respect to a single Product,
          as provided below, by giving written notice to that effect, as follows: 

		 

		(a)	by either party, if the other party is in material default or in material breach of any term or provision hereof
          or material breach of any representation or warranty in this Agreement, and such material default or material breach continues and is not remedied with thirty (30) days of notice of such default
          or breach, however that in case of non-supply by Sun pursuant to a confirmed purchase order, Sun is using its best efforts to effect such cure, Caraco shall not be entitled to terminate
          unless cure has not been resolved in 90 days.

			 
		(b)	by Caraco, for any given Product, if prior to a Product passing the applicable bioequivalence study or studies,
          Caraco in its reasonable discretion determines, prior to reasonable time in advance to the receipt of FDA approvals, that it would not be viable to develop and market the Product in the Territory,
          provided however that in that case the cost of development and/or studies incurred by Sun shall be shared between Sun and Caraco at mutually agreed upon proportions. 

			 
		(c)	by Sun for any given Product, in the event Caraco materially fails to perform its material obligations with respect
          to the Product, and fails to cure such failure within 

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        12

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON- PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

	 	thirty (30) days of notice of such failure from Sun (or if a cure is not reasonably possible within thirty days,
          such longer period as is necessary to cure such failure so long as it is agreed by Sun). In such event, Sun may elect to have the distribution rights for Sun ANDA Products terminated.

		 

		(d)	by either party in the event that there is a change of control of other party. 
			 
		(e)	by Sun if Caraco fails to obtain its fair market share for a specific product as stated under Section 1.5
          hereinabove.

			 
		(f)	by Sun without any cause or reason provided however that Caraco shall be entitled to receive the estimated amount
          of foregone profit, as mutually agreed to be worked out based upon the historical data for the Product, for the balance term of the Agreement for the relevant Product paid in quarterly increments. 

			 

	12.3	NO PREJUDICE TO RIGHTS. The termination of this Agreement or of any given Product shall be without prejudice to
          any rights and obligations of either party accrued prior to the effective date of such termination, unless explicitly otherwise agreed or otherwise provided in this Agreement. 

	 	 
	13.	CONFIDENTIALITY
	 	 
	13.1	During the term of this Agreement, each party may disclose to the other party (orally, in writing, or electronically),
          or a party may obtain, observe, or otherwise be granted access to, information and materials considered confidential by the other party. Confidential information includes, but is not limited
          to, non-public information relating to Products, compensation, research, services, developments, inventions, processes, protocols, methods of operation, techniques, strategies, programs (both
          software and firmware), designs, systems, proposed business arrangements, results of testing, distribution, engineering, marketing, financial, merchandising and/or sales information, individual
          customer profiles, customer lists and/or aggregated customer data (“Confidential Information”). Confidential Information must be marked or identified as “confidential” by
          the disclosing party, unless the information should reasonably be understood by the receiving party to be confidential or proprietary under the circumstances.

		 
	13.2	Each party shall use the other party’s Confidential Information only for the purposes of this Agreement, and
          not for its own or any third party’s benefit. Each party shall maintain the confidentiality of the other party’s Confidential Information in the same manner in which it protects its
          own Confidential Information of like kind, but in no event shall either party take 

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        13

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON- PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

	 	less than reasonable precautions to prevent the unauthorized disclosure or use of the other party’s Confidential
          Information. In addition, neither party shall make any unauthorized commercial use of the other party’s Confidential Information.

		 
	13.3	Except as expressly provided herein, each party is permitted to disclose the other party’s Confidential Information
          only to its employees and agents who have a need-to-know the Confidential Information in order for that party to exercise its rights and/or perform its obligations under this Agreement: (a) the
          party advises each such employee or agent of the confidential nature of the other party’s Confidential Information; and (b) each such employee and agent has agreed to comply with the provisions
          of this Agreement. Each party shall be and remain fully liable and responsible for its employees’
      and/or agents’ unauthorized disclosure or use of the other party’s Confidential Information.

		 
	13.4	Each party is permitted to disclose the other party’s Confidential Information as legally required in response
          to a court order, subpoena, administrative proceeding and/or similar legal process; provided that it gives the other party reasonable notice of the request, and an opportunity to defend and/or
          attempt to limit or prevent the disclosure of its Confidential Information.

		 
	13.5	The provisions of this Section shall not apply to information that the receiving party can prove: (a) was in its
          possession prior to receipt or disclosure hereunder; (b) was or became public knowledge through no fault of the receiving party or any of its employees or agents; (c) was lawfully disclosed to
          the receiving party by a third party through no breach of any obligation of confidentiality owed to the disclosing party; or (d) was created by the receiving party independently of any access
          to or use of the disclosing party’s Confidential Information.

		 
	13.6	Each party acknowledges and agrees that its unauthorized disclosure or use of the other party’s Confidential
          Information will cause damage to the other party that may not be adequately compensated through money damages. As such, each party expressly consents to the entry of an order for equitable remedies,
          including, but not limited to, temporary, preliminary and permanent injunctions to remedy any actual or threatened unauthorized disclosure or use of the disclosing party’s Confidential Information.
          These remedies are cumulative and in addition to all other remedies available at law or in equity.

		 
	13.7	At the disclosing party’s request, each party shall return the other party’s Confidential Information.
          Neither party shall use the other party’s Confidential Information for its own, or any third party’s, benefit. However, each party shall be permitted to retain and use a copy of 

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES,
            LTD.

	

        14

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON-PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

	 	the other party’s Confidential Information as reasonably necessary to exercise its rights that survive termination
          of this Agreement, provided that party continues to comply with its confidentiality obligations set forth herein. The provisions of this Section shall survive termination of this Agreement for
          so long as the Confidential Information remains confidential.

	 	 
	14. 	ARBITRATION.
	 	 
	 	Any dispute between the parties regarding any provision of this Agreement shall be resolved by binding arbitration
          in the Detroit, Michigan area pursuant to the commercial arbitration rules then prevailing of the American Arbitration Association. Judgment upon the award of the arbitrators may be entered by
          any court of competent jurisdiction.

	 	 
	15.	NO THIRD-PARTY BENEFICIARIES.
	 	 
	 	This Agreement shall not confer any rights or remedies upon any person other than the parties and their respective
          officers, directors, heirs, executors, administrators, successors, affiliates and associates and permitted assigns.

	 	 
	16.	FURTHER ASSURANCES.
	 	 
	 	The parties hereto hereby agree to execute and deliver to one another such further instruments and other documentation
          as may be requested by any other party hereto at any time and from time to time to carry out the terms of this Agreement. 

	 	 
	17. 	ENTIRE AGREEMENT.
	 	 
	 	This Agreement and the documents executed and delivered pursuant hereto constitute the entire agreement between
          the parties with respect to the subject matter contained herein, and supersede all prior and contemporaneous oral and written communications and agreements with respect thereto.

	 	 
	18.	BINDING EFFECT; ASSIGNMENT.
	 	 
	 	This Agreement shall be binding upon and shall insure to the benefit of the parties hereto and their heirs, executors,
          administrators, successors and assigns, affiliates and associates. No party has the right to assign any of its rights or obligations hereunder with the prior written consent of the other parties
          hereto, except that Sun and Caraco may assign this Agreement 

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        15

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON- PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

	 	and any of the provisions hereunder to any affiliate of Sun without the consent of Caraco, but Sun shall remain
          liable under this Agreement

	 	 
	19.	AFFILIATES.
	 	 
	 	Sun and Caraco agree and understand that Sun may perform some of its obligations through its affiliates; however,
          Sun is ultimately legally responsible for the actions of its affiliates. Any action of an affiliate of Sun under this Agreement which would constitute breach of this Agreement if performed directly
          by Sun constitutes a breach of this Agreement by Sun l. In addition, Caraco in taking any actions under this Agreement with affiliates of Sun shall thereby satisfy its obligations to Sun. This
          provision does not limit or restrict the rights of Caraco to pursue any right or remedy against any affiliate of Sun in connection with such affiliate’s performance of the obligations of
          Sun under this Agreement. 

	 	 
	20.	FORCE MAJEURE.
	 	 
	 	Neither party shall be liable for failure of performance, except for payment of money hereunder, if it is occasioned
          by Force Majeure such as wars, fire, explosion, flood, strike, lockout, embargo, Acts of God or of the government or any other cause beyond the control of the parties, provided that either of
          the parties has executed all reasonable efforts to remedy said circumstances.

	 	 
	21.	COUNTERPARTS.
	 	 
	 	This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of
          which together shall constitute one and the same instruments.

	 	 
	22.	HEADINGS. 
	 	 
	 	Headings of sections shall be deemed to be included for purposes of convenience only and shall not affect the interpretation
          of this Agreement. 

	 	 
	23.	NOTICES. 
	 	 
	 	Any notices or consents required or permitted by this Agreement shall be in writing and shall be deemed delivered
          if sent by certified mail, postage prepaid, return receipt requested, or overnight delivery service (receipt confirmed), or facsimile (receipt confirmed), as follows, unless such address is changed
          by written notice hereunder. 

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        16

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON- PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

	 	If to Caraco:	 	Caraco Pharmaceutical Laboratories Ltd.
	 	 	 	1150 Elijah McCoy Drive
	 	 	 	 Detroit, Michigan 48202
	 	 	 	Attn: Daniel H. Movens
	 	 	 	 
	 	With a copy to:	 	Steven R. Walker
	 	 	 	General Counsel
	 	 	 	Caraco Pharmaceutical Laboratories, Ltd.
	 	 	 	1150 Elijah McCoy Drive
	 	 	 	Detroit, MI 48202
	 	 	 	 
	 	If to Sun:	 	Sun Pharmaceutical Industries Limited
	 	 	 	Acme Plaza, Andheri - Kurla Road
	 	 	 	Andheri (East), Mumbai – 400059
	 	 	 	Attn: Mr. Dilip Shanghvi/Mr. Sudhir Valia

	 
	Any notice delivered hereunder shall be deemed given when actually received.        

	 	 
	24.	GOVERNING LAW.
	 	 
	 	This Agreement shall be governed by and construed in accordance with the laws of the State of Michigan, and the
          federal laws of the United States. 

	 	 
	25. 	AMENDMENTS AND WAIVERS. 
	 	 
	 	This Agreement may be amended and any provision hereof waived only in a writing signed by the party against whom
          an amendment or waiver is sought to be enforced. The parties hereto shall have the right at all times to enforce the provisions of this Agreement in strict accordance with the terms hereof, notwithstanding
          any conduct or custom on the part of such party in refraining from so doing at any time or times. The failure of any party at any time to enforce its rights under such provisions strictly in
          accordance with the same shall not be construed as having created a custom in any way or manner contrary to specific provisions of this Agreement or as having in any way or manner modified or
          waived the same. 

	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        17

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE
            NON- PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS SUBJECT
            TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 

	26. 	SEVERABILITY. 
		 
	 	If any provision of this Agreement shall be held invalid under any applicable law, such invalidity shall not affect
          any other provisions of this Agreement that can be given effect without the invalid provision, and, to this end, the provisions hereof are severable. 

	 	 
	27. 	EXPENSES. 
	 	 
	 	Except as otherwise expressly provided in this Agreement, the parties will bear their respective costs and expenses
          (including legal fees and expenses) incurred in connection with this Agreement and the transactions contemplated hereby. 

	 	 
	28.	CONSTRUCTION. 
	 	 
	 	The parties have participated jointly in the negotiation and drafting of this Agreement. In the event an ambiguity
          or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumption or burden of proof shall arise favoring or disfavoring
          any party by virtue of the authorship of any of the provisions of this Agreement. Any reference to any federal, state or local statute or law shall be deemed also to refer to all rules and regulations
          promulgated there under, unless the context requires otherwise. The word “including” shall mean including without limitation. Words used herein, regardless of the number and gender
          specifically used, shall be deemed and construed to include any other number, singular or plural, and any other gender, masculine, feminine or neuter, as the context requires. 

	 
	[Signature Page Follows]

    

	 
	 
	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        18

      

    

	CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN OMITTED BASED ON A REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC.
            THE NON- PUBLIC INFORMATION THAT HAS BEEN OMITTED FROM THE AGREEMENT HAS BEEN SEPARATELY FILED WITH THE SEC. EACH REDACTED PORTION OF THE AGREEMENT IS INDICATED BY A “[ * ]” AND IS
            SUBJECT TO THE REQUEST FOR CONFIDENTIAL TREATMENT SUBMITTED TO THE SEC. THE REDACTED INFORMATION IS CONFIDENTIAL INFORMATION OF CARACO PHARMACEUTICAL LABORATORIES, LTD.

	 
	IN WITNESS WHEREOF, the parties hereto have executed this Agreement, themselves or by their duly authorized representatives,
          under seal, the day and year first above written.

	 
	CARACO PHARMACEUTICAL LABORATORIES LTD
	 

	By:	          /s/ Daniel H. Movens 	 
	 	
	 
	 	          (signature)	 
	 	 	 
	Name:	          Daniel H. Movens 	 
	 	
	 
	 	          (printed)	 
	 	 	 
	Title:	          Chief Executive Officer 	 
	 	
	 
	 	 	 
	Date:	          	 
	 	
	 
	 	 	 

	 
	SUN PHARMACEUTICAL INDUSTRIES LIMITED

	 	 	 
	By:	          /s/ Dilip S. Shanghvi	 
	 	
	 
	 	          (signature)	 
	 	 	 
	Name:	          Dilip S. Shanghvi 	 
	 	
	 
	 	          (printed)	 
	 	 	 
	Title:	          Chairman 	 
	 	
	 
	 	 	 
	Date:	          	 
	 	
	 
	 	 	 

	[ * ] CONFIDENTIAL TREATMENT REQUESTED BY CARACO PHARMACEUTICAL LABORATORIES, LTD.

	

        19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00131-of-00352.parquet"}]]